US Pat. No. 9,478,914

MICRO PLUG AND KEYED MICRO RECEPTACLE

SANOFI-AVENTIS DEUTSCHLAN...

1. A micro plug being insertable into a standard micro receptacle, preferably a Universal Serial Bus Micro-USB receptacle,
said micro plug comprising:
a housing,
at least two contact pins attached to said housing,
a shield attached to said housing and at least partially laterally enclosing said at least two contact pins,
a fastener, and
at least one recess arranged in a portion of said shield,
wherein said at least one recess is configured to receive a projection of a correspondingly modified standard micro receptacle
when said micro plug is inserted into said modified standard micro receptacle, and wherein said portion of said shield is
laterally defined by said fastener.

US Pat. No. 9,336,690

TRAINING MECHANISM FOR DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A cartridge for a drug delivery device comprising:
a body of substantially cylindrical shape,
a piston slidably disposed in the body along two opposite axial directions, along a distal and along a proximal direction,
at least one friction means operably engaged with the piston to generate a pre-defined friction force between the piston and
an inside wall of the body, when the piston is displaced relative to the body,

wherein in response to an axial displacement of the piston relative to the body in distal direction and in proximal direction,
the at least one friction means is adapted to generate respective proximal and distal friction forces that are different in
magnitude,

wherein the friction means comprises at least one friction member slidably disposed in axial direction in at least one receptacle
of the piston.

US Pat. No. 9,260,454

ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS

SANOFI, Paris (FR)

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a
pharmaceutically acceptable salt thereof,

wherein
X is selected from the series consisting of ?N— and ?N(O)—;
R1, R2 and R3 are independently of one another selected from the series consisting of hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O—, nitro, cyano, (C1-C4)-alkyl-O—C(O)—, R4-N(R5)-C(O)— and R6-N(R7)-S(O)2—;

R4 is selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C4)-alkyl-, phenyl, phenyl-(C1-C4)-alkyl-, Het1 and Het1-(C1-C4)-alkyl-, wherein Het1 is optionally substituted by one or more identical or different substituents R8;

R5, R6 and R7 are independently of one another selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl and (C3-C7)-cycloalkyl-(C1-C4)-alkyl-;

R8 is selected from the series consisting of halogen, (C1-C4)-alkyl, hydroxy, oxo, (C1-C4)-alkyl-O— and cyano;

R10 is selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C4)-alkyl- and (C1-C4)-alkyl-O—(C1-C4)-alkyl-, with the proviso that R10 can only be hydrogen if X is ?N(O)—;

R11 is selected from the series consisting of (C1-C4)-alkyl which is optionally substituted by one or more identical or different substituents R12, (C3-C7)-cycloalkyl which is optionally substituted by one or more identical or different substituents R13, and Het2 which is optionally
substituted by one or more identical or different substituents R14 and wherein Het2 is bonded via a ring carbon atom;

or the groups R10 and R11, together with the nitrogen atom carrying them, form a 4-membered to 12-membered, monocyclic or
bicyclic, saturated or partially unsaturated heterocycle which, in addition to the nitrogen atom carrying R10 and R11, comprises
0, 1 or 2 further ring heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur, which is optionally
substituted on ring carbon atoms by one or more identical or different substituents R30, and which is optionally substituted
on further ring nitrogen atoms by one or more identical or different substituents R40;

R12 is selected from the series consisting of (C3-C7)-cycloalkyl, phenyl, Het3, hydroxy, (C1-C4)-alkyl-O—, (C1-C4)-alkyl-C(O)—O—, R15-N(R16)- and R17-C(O)—N(R18)-, wherein phenyl and Het3 independently of one another are optionally substituted
by one or more identical or different substituents R19;

R13 is selected from the series consisting of hydroxy, (C1-C4)-alkyl-O—, (C1-C4)-alkyl-C(O)—O— and cyano;

R14 is selected from the series consisting of fluorine, (C1-C4)-alkyl, hydroxy, (C1-C4)-alkyl-O—, (C1-C4)-alkyl-C(O)—O—, HO—(C1-C4)-alkyl-, (C1-C4)-alkyl-O—(C1-C4)-alkyl-, (C1-C4)-alkyl-C(O)—O—(C1-C4)-alkyl- and (C1-C4)-alkyl-C(O)—;

R15, R16 and R18 are independently of one another selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl and (C3-C7)-cycloalkyl-(C1-C4)-alkyl-;

R17 is selected from the series consisting of (C1-C4)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C4)-alkyl-, phenyl and phenyl-(C1-C4)-alkyl-;

R19 is selected from the series consisting of halogen, (C1-C4)-alkyl, hydroxy, (C1-C4)-alkyl-O—, (C1-C4)-alkyl-C(O)—O—, cyano, R20-O—C(O)— and R21-N(R22)-C(O)—;

R20, R21 and R22 are independently of one another selected from the series consisting of hydrogen and (C1-C4)-alkyl;

R30 is selected from the series consisting of fluorine, (C1-C4)-alkyl, Het2, hydroxy, oxo, (C1-C4)-alkyl-O—, R31-N(R32)-, (C1-C4)-alkyl-C(O)—, R33-O—C(O)— and R34-N(R35)-C(O)—, wherein Het2 is optionally substituted by one or more identical or different
substituents R36;

R31, R32, R33, R34 and R35 are independently of one another selected from the series consisting of hydrogen and (C1-C4)-alkyl;

R36 is selected from the series consisting of fluorine, (C1-C4)-alkyl, hydroxy and oxo;

R40 is selected from the series consisting of (C1-C4)-alkyl which is optionally substituted by one or more identical or different substituents R41, (C3-C7)-cycloalkyl which is optionally substituted by one or more identical or different substituents R42, phenyl which is optionally
substituted by one or more identical or different substituents R43, Het1 which is optionally substituted by one or more identical
or different substituents R44, (C1-C4)-alkyl-C(O)— which is optionally substituted by one or more identical or different substituents R45, (C3-C7)-cycloalkyl-C(O)— which is optionally substituted by one or more identical or different substituents R46, phenyl-C(O)— which
is optionally substituted by one or more identical or different substituents R47, Het3-C(O)— which is optionally substituted
by one or more identical or different substituents R48 and wherein Het3 is bonded via a ring carbon atom, R49-N(R50)-C(O)—,
(C1-C4)-alkyl-S(O)2— and R51-N(R52)-S(O)2—;

R41 is selected from the series consisting of (C3-C7)-cycloalkyl, hydroxy, (C1-C4)-alkyl-O—, R60-N(R61)-, R62-O—C(O)— and R63-N(R64)-C(O)—;

R42 is selected from the series consisting of hydroxy and R65-N(R66)-;
R43 is selected from the series consisting of halogen, (C1-C4)-alkyl, hydroxy, (C1-C4)-alkyl-O—, cyano, R67-O—C(O)— and R68-N(R69)-C(O)—;

R44 is selected from the series consisting of halogen, (C1-C4)-alkyl, hydroxy, oxo, (C1-C4)-alkyl-O—, R70-N(R71)-, (C1-C4)-alkyl-C(O)—N(R72)-, (C1-C4)-alkyl-S(O)2—N(R73)- and Het4, wherein Het4 is optionally substituted by one or more identical or different substituents R74;

R45 is selected from the series consisting of (C3-C7)-cycloalkyl, cyano, hydroxy, (C1-C4)-alkyl-O—, phenyl-O—, phenyl-(C1-C4)-alkyl-O—, oxo, R75-N(R76)- and R77-C(O)—N(R78)-;

R46 is selected from the series consisting of hydroxy and R79-N(R80)-;
R47 is selected from the series consisting of halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O— and R81-N(R82)-C(O)—;

R48 is selected from the series consisting of halogen, (C1-C4)-alkyl, hydroxy, oxo and (C1-C4)-alkyl-O—;

R49 and R51 are independently of one another selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C4)-alkyl-, phenyl and phenyl-(C1-C4)-alkyl-;

R50 and R52 are independently of one another selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl and (C3-C7)-cycloalkyl-(C1-C4)-alkyl-;

R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R76, R78, R79, R80, R81, R82, R83 and R84 are independently
of one another selected from the series consisting of hydrogen and (C1-C4)-alkyl;

R74 is selected from the series consisting of fluorine and (C1-C4)-alkyl;

R75 is selected from the series consisting of hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C4)-alkyl-, phenyl and phenyl-(C1-C4)-alkyl-;

R77 is selected from the series consisting of (C1-C4)-alkyl and R83-N(R84)-(C1-C4)-alkyl-;

Het1 is a monocyclic, 4-membered to 7-membered, saturated, partially unsaturated or aromatic heterocycle which comprises 1,
2 or 3 identical or different ring heteroatoms selected from the series consisting of nitrogen oxygen and sulfur, and which
is bonded via a ring carbon atom;

Het2 is a monocyclic, 4-membered to 7-membered, saturated heterocycle which comprises 1 or 2 identical or different ring heteroatoms
selected from the series consisting of nitrogen, oxygen and sulfur;

Het3 is a monocyclic or bicyclic, 4-membered to 12-membered, saturated, partially unsaturated or aromatic heterocycle which
comprises 1, 2 or 3 identical or different ring heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur;

Het4 is a monocyclic, 4-membered to 7-membered, saturated heterocycle which comprises a ring nitrogen atom via which Het4
is bonded, and 0 or 1 further ring heteroatom selected from the series consisting of nitrogen, oxygen and sulfur;

wherein all phenyl groups are optionally substituted by one or more identical or different substituents selected from the
series consisting of halogen, (C1-C4)-alkyl, cyano, hydroxy and (C1-C4)-alkyl-O—, unless specified otherwise;

wherein all cycloalkyl groups, independently of any other substituents which can be present on a cycloalkyl group, are optionally
substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C1-C4)-alkyl;

wherein all alkyl groups, independently of any other substituents which can be present on an alkyl group, are optionally substituted
by one or more fluorine substituents;

with the proviso that the compound of the formula I is not 3-oxo-3H-isothiazolo[5,4-b]pyridine-2-carboxylic acid diethylamide.

US Pat. No. 9,156,796

BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS

SANOFI, Paris (FR)

1. A compound of the formula I,

wherein
R?, R?, and R?? are independently of each other H, halogen, CF3, OCF3, or O—(C1-C3)-alkyl;

R1 is

a) (C4-C7)-alkyl;

b) (C5-C7)-cycloalkyl, which is unsubstituted or mono-substituted by (C1-C2)-alkyl or CF3;

c) methylene-cyclohexyl; or
d) phenyl, which is unsubstituted or mono-substituted by methyl or Cl;
R2 is

a) a 5-membered heteroaryl which contains 1 or 2 identical or different ring heteroatoms selected from the group consisting
of N, O and S, wherein said 5-membered heteroaryl is unsubstituted or mono-substituted by Cl or (C1-C4)-alkyl;

b) phenyl;
c) (C5-C6)-cycloalkyl; or

d) tetrahydrofuranyl;
R3 is H or (C1-C2)-alkyl;

and
R4 is

a) (C3-C5)-alkyl, which may be optionally substituted by 1-3 F or S—(C1-C4)-alkyl,

b) (C0-C1)-alkylene-(C3-C7)-cycloalkyl, wherein said cycloalkyl is unsubstituted or mono- or di-substituted by methyl;

c) (C0-C2)-alkylene-phenyl, wherein said phenyl is unsubstituted or mono- or di-substituted by F, Cl, (C1-C4)-alkyl or CF3; or

d) thienyl; or
R3 and R4
are, together with the carbon atom to which they are attached, a 5- to 7-membered cycloalkyl ring, which is unsubstituted
or mono-substituted by (C1-C4)-alkyl;

R5 is H, (C1-C4)-alkyl or OH;

R6 is H or (C1-C4)-alkyl;

n is 0, 1 or 2; and
Z is
CO2—R7, OR8, C(O)NR9R10, S(O)2NR11R12,


wherein
v is 0 or 2;
R7 is H or (C1-C4)-alkyl;

R8 is H or (C1-C4)-alkyl;

R9 is H, (C1-C4)-alkyl or ethylene-O—(C1-C4)-alkyl;

and
R10 is

a) H;
b) (C1-C6)-alkyl, which is unsubstituted or mono-substituted by CF3;

c) (C1-C2)-alkyl, which is substituted by CN or CO2R19;

wherein
R19 is H or (C1-C6)-alkyl;

d) (C2-C4)-alkyl, which is mono-substituted by a substituent selected from the group consisting of S-methyl, SO2NR20R21, O—R22 and NR23R24;

wherein
R20 is H;

R21 is H;

R22 is H, (C1-C3)-alkyl, methylene-cyclopropyl, methylene-phenyl, or methylene-2-tetrahydrofurane;

R23 is H or (C1-C2)-alkyl; and

R24 is (C1-C2)-alkyl or SO2-methyl;

e) (C3-C5)-cycloalkyl, which is unsubstituted or mono-substituted by phenyl;

f) (C0-C2)-alkylene-heterocycloalkyl, wherein said heterocycloalkyl is five or six membered and contains 1 or 2 O atoms in non-adjacent
positions, and wherein said heterocycloalkyl is unsubstituted or geminally disubstituted with a spiro cyclopentyl ring or
a spiro cyclohexyl ring;

g) (C2-C5)-alkylene-heterocycloalkyl, wherein said heterocycloalkyl is a five-, six- or seven-membered ring, which contains at least
one N atom, and which is attached via said N-atom, and which may additionally contain one heteroatom selected from the group
consisting of O, S(O)x and NR25 in a position not adjacent to the N atom by which the ring is attached to the alkylene, and wherein any carbon atom within
said heterocycloalkyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of (C1-C3)alkyl and methylene-phenyl; wherein

x is 2; and
R25 is H, (C1-C2)alkyl, methylene-phenyl or phenyl, which is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting
of F, Cl and O—(C1-C4)-alkyl;

h) (C0-C3)-alkylene-heterocycloalkyl, wherein said heterocycloalkyl is a five- or six-membered ring, which contains at least one N
atom, and which is not attached via said N-atom, and which may additionally contain one O atom in a position not adjacent
to the N atom, and wherein said N-atom is unsubstituted or substituted by a substituent selected from the group consisting
of

i) (C1-C4)-alkyl, which is unsubstituted or mono-substituted by O(C1-C4)-alkyl;

ii) methylene-cyclohexyl;
iii) (C0-C2)-alkylene-phenyl, wherein said phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting
of F and O(C1-C4)-alkyl;

iv) (C0-C1)-alkylene-pyridyl; and

v) pyrimidinyl;
i) 8-methyl-8-aza-bicyclo[3.2.1]oct-3yl;
j) 9-methyl-9-aza-bicyclo[3.3.1]non-3-yl;
k) methylene-4-(octahydro-quinolizinyl);
l) (C0-C2)-alkylene-phenyl, wherein phenyl is unsubstituted or monosubstituted by a substituent selected from the group consisting
of F, O(C1-C4)-alkyl, N((C1-C4)-alkyl)2, 4-morpholinyl and methylene-(4-methyl-piperidin)-1-yl or disubstituted on adjacent positions by the group —O(CH2)O—; or

m) (C1-C2)-alkylene-heteroaryl, wherein said heteroaryl ring is a five- or six-membered ring containing 1, 2, 3 or 4 heteroatoms selected
from the group consisting of O, S and N; and wherein said heteroaryl ring is unsubstituted;

or
R9 and R10 together with the N-atom carrying them are

a) a four-, five- or six-membered heterocycloalkyl ring containing one heteroatom, which is the N atom to which R9 and R10 are attached, and wherein said heterocycloalkyl ring is unsubstituted or mono-substituted by a substituent selected from the
group consisting of

i) (C0-C1)-alkylene-OR26, wherein R26 is H, (C1-C3)alkyl or methylene-phenyl;

ii) CO2R27, wherein R27 is H or (C1-C6)-alkyl;

ii) NR28R29, wherein R28 is (C1-C2)-alkyl and R29 is (C1-C2)-alkyl, methylene-phenyl or ethylene-N((C1-C4)-alkyl)2;

iii) 1-piperidinyl, which is unsubstituted or mono-substituted by methyl;
iv) 1-piperazinyl, which is unsubstituted or mono-substituted by methyl;
v) 4-morpholinyl;
vi) 1-azepanyl; and
vii) 2-(2,3-dihydro-1H-isoindolyl);
b) a six- or seven-membered heterocycloalkyl ring containing the N atom to which R9 and R10 are attached and one additional heteroatom selected from O, S or NR30 in a position non-adjacent to the N atom to which R9 and R10 are attached, wherein the carbon atoms in said heterocycloalkyl ring are unsubstituted or mono- or disubstituted by methyl
and wherein

R30 is

i) H;
ii) (C1-C4)-alkyl;

iii) (C5-C6)-cycloalkyl;

iv) phenyl, which is unsubstituted or mono-substituted by F, CF3 or O—(C1-C4)-alkyl;

v) methylene-phenyl, which is unsubstituted or mono- or di-substituted by F or Cl or disubstituted on adjacent positions by
the group —O(CH2)O—; or

vi) pyridyl; or
c) a 2,5-diaza-bicyclo[2.2.1]heptyl-ring, which is unsubstituted or substituted on the N atom in the 5-position by a substituent
selected from the group consisting of (C1-C4)-alkyl, methylene-cyclopentyl, phenyl, which is unsubstituted or mono-substituted by F, and methylene-phenyl, wherein said
phenyl is unsubstituted or mono-substituted by O—(C1-C4)-alkyl or CF3;

R11 is H;

R12 is (C1-C4)-alkyl;

R13 is H;

R14 is CF3 or methylene-O—(C1-C4)-alkyl;

R15 is cyclopropyl or phenyl;

R16 is H or (C1-C4)-alkyl;

R17 is H or (C1-C4)-alkyl;

and
R18 is (C1-C4)-alkyl;

in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt
thereof, or a physiologically acceptable solvate of any of them.

US Pat. No. 9,216,255

NEEDLE ASSEMBLY

Sanofi-Aventis Deutschlan...

1. A needle assembly for a drug delivery device, wherein the needle assembly comprises
a needle seal,
a needle retainer and a needle, wherein
the needle retainer secures the needle against displacement with respect to said needle retainer when a dose of a drug is
being delivered, wherein the needle retainer is in an original state until the dose is delivered,

the needle retainer is made of a flexible material, and
said needle seal is configured to push onto, compress, and deform the needle retainer after delivering the dose of the drug,
thereby unlocking the needle from the needle retainer, wherein

the needle retainer is configured to bow radially outwards with respect to the needle when the needle seal is deforming the
needle retainer, and

the needle retainer is configured to spring back into the original state after the needle is retracted into the drug delivery
device.

US Pat. No. 9,111,404

VENDING APPARATUS AND METHOD FOR PROVIDING TRAINING FOR A MEDICINAL PRODUCT OR MEDICAL DEVICE OR COMBINATION PRODUCT

Sanofi-Aventis Deutschlan...

1. A vending apparatus for at least one medicinal product, comprising:
a housing,
storage means adapted to store the at least one medicinal product,
an input means adapted to process a costumer request for a medicinal product,
processing means adapted to process the costumer request and being adapted to execute a product-related training procedure
with the customer, and

delivery means for handing out the medicinal product to the costumer after passing the training procedure, wherein
access to the medicinal product is only approved by the processing means if the customer successfully passes the training
procedure.

US Pat. No. 9,345,845

NEEDLE HUB AND VALVE FOR NEEDLE HUB

SANOFI-AVENTIS DEUTSCHLAN...

1. An apparatus comprising:
a valve body comprising a first inlet opening, a second inlet opening, an outlet opening, and a central space connecting the
first inlet opening, the second inlet opening, and the outlet opening, and

a spherical element movably contained inside the central space configured for translatory movement and configured to seal
either the first inlet opening or the second inlet opening,

wherein the first inlet opening and the second inlet opening are configured for fluid communication with a first reservoir
and a second reservoir, respectively,

wherein the outlet opening is configured for fluid connection with a septum.

US Pat. No. 9,347,930

DISPENSING MECHANISM FOR TEST STRIPS

SANOFI-AVENTIS DEUTSCHLAN...

1. Dispensing mechanism for dispensing measurement strips, comprising:
a strip cartridge with an enclosure for retaining a plurality of measurement strips and a dispensing slot for dispensing one
measurement strip at a time,

a spring rotatably arranged with respect to the strip cartridge, the spring comprising at least one engagement section adapted
to engage one of the measurement strips at a time and move it out of the dispensing slot when the spring is rotated,

a guide slot arranged in the strip cartridge for guiding the engagement section of the spring as the spring is rotated.

US Pat. No. 9,314,194

TISSUE PENETRATION DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A body fluid sampling system for use on a tissue site, the system comprising:
a drive force generator;
a plurality of penetrating members at least partially housed in a penetrating member housing, the penetrating member housing
having a plurality of openings with each of the plurality of openings associated with one of the plurality of penetrating
members, each of the plurality of penetrating members being configured to be coupled to the drive force generator and be launched
along a launch path through an opening in the penetrating member housing; and

a plurality of analyte sensors housed in an analyte sensor housing, each of an analyte sensor being associated with one of
the plurality of penetrating members, the analyte sensor housing and the penetrating member housing being coupled to provide
that each of the plurality of analyte sensors is aligned to and positioned out of the launch path of one of the plurality
of penetrating members,

one or more seals that seal the plurality of penetrating members in the penetrating member housing and the plurality of analyte
sensors in the analyte sensor housing separately to keep each of the plurality of penetrating members sterile and each of
the plurality of analyte sensors dry wherein the seals are removable for launch of one of the penetrating members and for
use of one of the analyte sensors.

US Pat. No. 9,155,842

MEDICATION DELIVERY DEVICE AND METHOD OF ASSEMBLING A MEDICATION DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A medication delivery device comprising:
an indicator element having indications,
a magnifying device located over an indication position of the indicator element,
wherein the magnifying device comprises an optical system comprising a magnifying lens, and wherein the optical system is
constructed such that the optical path length between the indication position and the magnifying lens is enlarged in comparison
to a direct geometrical distance between the indication position and the magnifying lens.

US Pat. No. 9,463,282

ARRANGEMENT FOR COUPLING A PLUNGER TO EITHER A SYRINGE OR A STOPPER

Sanofi-Aventis Deutschlan...

4. An auto-injector for administering a dose of medicament, comprising:
an elongate housing comprising an inner surface having a first portion and a second portion, the second portion being wider
than the first portion, the housing being arranged to contain a syringe in a slidable manner within the housing, and the syringe
comprising a hollow needle and a stopper for sealing the syringe and displacing the medicament, and the housing having a distal
end and a proximal end with an orifice intended to be applied against an injection site;

a drive mechanism arranged in the housing, the drive mechanism being configured to, upon activation, push the needle from
a covered position inside the housing into an advanced position through the orifice and past the proximal end of the housing
via a plunger, and operate the syringe to supply the dose of medicament via the plunger;

an activating mechanism arranged in the housing to block the drive mechanism prior to manual operation of the activating mechanism,
the activating mechanism being configured to, upon manual operation, activate the drive mechanism for injection; and

a syringe holder slidably arranged in a housing and configured to be coupled to the syringe, the syringe holder comprising
a resilient syringe holder arm having a first end and a second end, the first end of the syringe holder arm being attached
to a distal end of the syringe holder, and the second end of the syringe holder arm having an inclined surface for bearing
against a shoulder of the plunger,

wherein the syringe holder arm is configured to be supported by a first portion of an inner surface of the housing to inhibit
the syringe holder arm from being flexed outward when the syringe holder arm is in a first position,

wherein the syringe holder arm is configured such that the inclined surface of the second end of the syringe holder arm engages
the shoulder of the plunger to connect the syringe holder arm to the plunger when the syringe holder arm is in the first position,
and

wherein the syringe holder arm is configured to flex outwards into a second portion of the inner surface of the housing and
to disengage the inclined surface of the second end from the shoulder of the plunger such that the syringe holder arm is disconnected
from the plunger and engages with the stopper when the syringe holder arm is in a second position proximal to the first position.

US Pat. No. 9,302,057

NEEDLE ASSEMBLY REUSE PREVENTION MECHANISM

Sanofi-Aventis Deutschlan...

1. A needle assembly reuse prevention mechanism comprising:
a barrier movable between a retracted position and an extended position, the barrier comprising a stem and an arm, the arm
having a first portion connected to the stem and a second portion connected to the first portion at a right angle, the stem
comprising a spring coupled to the barrier, and the spring biasing the barrier in a first direction, wherein when in the extended
position, the barrier substantially covers an opening of a needle assembly storage compartment of a needle assembly storage
device;

a pin formed on the barrier and disposed on a lateral surface of the second portion of the arm; and
a slot receiving the pin, the slot having at least one abutment face for abutting the pin and preventing movement of the barrier
in the first direction.

US Pat. No. 9,221,917

DUAL VARIABLE REGION ANTIBODY-LIKE BINDING PROTEINS HAVING CROSS-OVER BINDING REGION ORIENTATION

SANOFI, Paris (FR)

1. An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, wherein two polypeptide
chains have a structure represented by the formula:
VL1-L1-VL2-L2-CL  [I]
and two polypeptide chains have a structure represented by the formula:
VH2-L3-VH1-L4-CH1-Fc  [II]
wherein:
VL1 is a first immunoglobulin light chain variable domain;

VL2 is a second immunoglobulin light chain variable domain;

VH1 is a first immunoglobulin heavy chain variable domain;

VH2 is a second immunoglobulin heavy chain variable domain;

CL is an immunoglobulin light chain constant domain;

CH1 is the immunoglobulin CH1 heavy chain constant domain;

Fc is the immunoglobulin hinge region and CH2, CH3 immunoglobulin heavy chain constant domains; and

L1, L2, L3, and L4 are amino acid linkers;
wherein L2 and L4 are both at least one amino acid in length, and
(a) the length of L2 is at least twice the length of L4; or

(b) the length of L4 is at least twice the length of L2;
and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair.

US Pat. No. 9,278,137

POLYMERIC CONJUGATES OF ACTIVE PRINCIPLES, THEIR PROCESS OF PREPARATION AND THEIR POLYMERIC INTERMEDIATES

SANOFI, Paris (FR) CENTR...

1. Conjugate of an active principle and of a copolymer of polyethylene glycol and polylactic acid of formula (I):
in which:
mPEG is a methoxy-polyethylene glycol;
PLA is a polylactic acid;
m is the average molecular weight of the polyethylene glycol fragment (mPEG) and is comprised between 100 and 15 000 (expressed
in Da);

n is the average molecular weight of the polylactic acid fragment and is comprised between 1000 and 50 000 (expressed in Da);
AP is an active principle residue;
L is a linker, such that L is a dicarboxylate derivative of succinic acid, glutaric acid or diglycolic acid,
X is a hydrogen atom or an alkyl group optionally substituted by one or more substituents selected from halogen atoms, OR,
CN, CF3, NRR? and COOR groups, where R and R?, which are identical to or different from one another, are a hydrogen atom or an alkyl
group,
and their pharmaceutically acceptable salts.

US Pat. No. 9,138,462

PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE

SANOFI-AVENTIS DEUTSCHLAN...

1. A prodrug comprising:
a hydrogel (Z) with backbone moieties of formula C-(A-Hyp)4, wherein:

each A is independently selected from the formula —(CH2)n1(OCH2CH2)nX?—,

wherein:
n1 is 1 or 2;
n is an integer ranging from 5 to 50; and
X? is an amide linkage linking A and Hyp;
each Hyp is independently selected from hyperbranched polypeptides comprising lysine;
the backbone moieties are crosslinked by poly(ethylene glycol)-based crosslinker moieties, comprising m ethylene glycol units,
wherein m is an integer ranging from 3-100, and terminated by at least two hydrolytically degradable bonds;

a linker L2 connected to a backbone moiety, wherein:

L2 is a single chemical bond or is a C1-20 alkyl chain, which is optionally interrupted by one or more groups independently selected from —O— and C(O)N(R3aa) and is optionally substituted with one or more groups independently selected from OH and C(O)N(R3aaR3aaa), wherein R3aa and R3aaa are independently selected from the group consisting of H and C1-4 alkyl; and

L2 is attached to Z via a terminal group selected from the group consisting of


wherein L2 is attached to the sulfur atom in structure X and Z is attached to the nitrogen atom in structure X or L2 is attached to the nitrogen atom in structure XI and Z is attached to the sulfur atom in structure XI; and

an insulin-linker conjugate D-L1, wherein:

D is insulin; and
L1 is:


wherein:
the dashed line indicates the point of attachment of L1 to one of the amino groups of insulin through an amide bond;

X is C(R3R3a);

R1a and R3a are independently selected from the group consisting of H, NH(R2b), N(R2b)C(O)R4 and C1-4 alkyl and optionally substituted with L2-Z;

R1, R2, R2a, R2b, R3, and R4 are independently selected from the group consisting of H and C1-4 alkyl, and optionally substituted with L2-Z; and

L1 is substituted with one L2-Z provided that the hydrogen marked with the asterisk in formula (I) is not replaced;
or a pharmaceutically acceptable salt thereof, wherein said prodrug is in the form of microparticles.

US Pat. No. 9,132,237

DRUG DELIVERY DEVICE AND METHOD OF MANUFACTURING A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device comprising:
a housing with a proximal end and a distal end,
a cartridge adapted to accommodate a drug,
a cartridge retaining member adapted to retain the cartridge, the cartridge retaining member releasably secured to the housing,
and

a spring washer arranged within the housing so as to exert a force on the cartridge and to secure the cartridge against movement
with respect to the cartridge retaining member,

wherein the spring washer has at least two fixing elements configured to axially and rotationally fix the spring washer relative
to the housing.

US Pat. No. 9,333,304

NEEDLE SAFETY ARRANGEMENT AND METHOD FOR OPERATING IT

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament (M), the auto-injector having a distal end (P) and a proximal
end (D) with an orifice intended to be applied against an injection site and comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), wherein the syringe is slidably arranged with respect to the housing,

a driver capable of, upon activation:
pushing the needle from a retracted position into an advanced position through the orifice and past the proximal end (P),
and

operating the syringe to supply the dose of medicament (M),
a plunger for transmitting power from the driver to at least one of the syringe or the stopper,
an activator arranged to lock the driver in a compressed state prior to manual operation and capable of, upon manual operation,
releasing the driver for injection,

wherein translation of the needle and the syringe or translation of the plunger in a longitudinal direction is controlled
by at least one ramp or one thread so as to cause the syringe or the plunger to rotate, during administering the dose of the
liquid medicament, about a longitudinal axis of the auto-injector when translated at least during part of the translation.

US Pat. No. 9,242,046

CODED CARTRIDGE ASSEMBLY

SANOFI-AVENTIS DEUTSCHLAN...

1. A cartridge assembly and a dose setting and delivery mechanism comprising:
a cylindrical body for holding a medicament reservoir, where the cylindrical body has a proximal end portion having an outer
surface and an inner surface;

a fastener on the outer surface of the proximal end portion of the cylindrical body;
a corresponding fastener on a distal inner surface of the dose setting and delivery mechanism, where the fastener is configured
to attach the cartridge assembly to the dose setting and delivery mechanism through a combination of axial and rotational
movements; and

a pin projecting radially outward from the proximal end portion configured to engage a corresponding pin located on the distal
inner surface of the dose setting and delivery mechanism, where the pin is separate from the fastener and is configured to
engage the corresponding pin, blocking travel in the connection process of the cartridge assembly and thereby allowing the
cartridge assembly to operably connect to the dose setting and delivery mechanism.

US Pat. No. 9,457,066

PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE

SANOFI-AVENTIS DEUTSCHLAN...

1. A prodrug comprising:
a hydrogel (Z) with backbone moieties of formula C-(A-Hyp)4, wherein:

each A is independently selected from the formula —(CH2)n1(OCH2CH2)nX?—, wherein:

n1 is 1 or 2;
n is an integer ranging from 5 to 50; and
X? is an amide linkage linking A and Hyp;
each Hyp is independently selected from hyperbranched polypeptides comprising lysine;
the backbone moieties are crosslinked by poly(ethylene glycol)-based crosslinker moieties, comprising m ethylene glycol units,
wherein m is an integer ranging from 10-70, and terminated by at least two hydrolytically degradable bonds;

a linker L2 connected to the backbone moiety, wherein:

L2 is a single chemical bond or is a C1-20 alkyl chain, which is optionally interrupted by one or more groups independently selected from —O— and C(O)N(R3aa), and further optionally substituted with one or more groups independently selected from OH and C(O)N(R3aaR3aaa), wherein R3aa and R3aaa are independently selected from the group consisting of H and C1-4 alkyl; and

L2 is attached to Z via a terminal group selected from the group consisting of


 wherein L2 is attached to the sulfur atom in structure X and Z is attached to the nitrogen atom in structure X, or L2 is attached to the nitrogen atom in structure XI and Z is attached to the sulfur atom in structure XI; and

an insulin-linker conjugate D-L1, wherein:

D is an insulin; and
L1 is:


 wherein:
the dashed line indicates the point of attachment of L1 to one of the amino groups of insulin through an amide bond;

X is N(R3);

R1a is selected from the group consisting of H, NH(R2b), N(R2b)C(O)R4, and C1-4 alkyl;

R1, R2, R2a, R2b, R3, and R4 are independently selected from the group consisting of H and C1-4 alkyl, and optionally substituted with L2-Z; and

L1 is substituted with one L2-Z provided that the hydrogen marked with the asterisk in formula (I) is not replaced;
or a pharmaceutically acceptable salt thereof, wherein said prodrug is in the form of microparticles.

US Pat. No. 9,265,723

LONG ACTING INSULIN COMPOSITION

SANOFI-AVENTIS DEUTSCHLAN...

1. A pharmaceutical liquid composition comprising an insulin compound in a concentration of at least 10 mg/ml characterized
by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound, wherein the insulin compound
is covalently linked to a depot, and
wherein the insulin compound is a prodrug or a pharmaceutical acceptable salt thereof, said insulin compound comprising (1)
a hydrogel (Z) with backbone moieties of formula C(-A-Hyp)4, wherein each A is independently selected from the formula -(CH2)n1 (OCH2CH2)nX?-, wherein

n1 is 1 or 2;

n is an integer ranging from 5 to 50;
X? is an amide linkage linking A and Hyp:
each Hyp is independently selected from hyperbranched polypeptide comprising lysine;
the backbone moieties are crosslinked by poly(ethylene glycol)- based crosslinker moieties, comprising m ethylene glycol units,
where m is an integer ranging from 3-100 and terminated by at least two hydrolytically degradable bonds;

(ii) a linker L2 connected to a backbone moiety, wherein L2 is a single chemical bond or spacer and L2 is attached to Z via a terminal group selected from the group consisting of


wherein L2 is attached to the sulfur atom in structure X and Z is attached to the nitrogen atom in structure X or L2 is attached to the nitrogen atom in structure XI and Z is attached to the sulfur atom in structure XI; and

(iii) an insulin conjugate D-L1, wherein

D represents the insulin moiety; and
-L1 is


wherein the dashed line indicates the attachment of L1 to one of the amino groups of insulin by forming an amide bond;

X is C(R3R3a) or N(R3);

R1a and R3a are independently selected from the group consisting H, NH(R2b), N(R2b)C(O)R4 and C1-4 alkyl;

R1, R2 R2a, R2b, R3 and R4 are independently selected from the group consisting of H and C1-4 alkyl,

wherein L1 is substituted with one L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced
by a substituent.

US Pat. No. 9,125,991

DEVICE AND METHOD FOR DETERMINING INFORMATION RELATED TO A MEDICAL DEVICE

Sanofi-Aventis Deutschlan...

1. An apparatus comprising:
a mating unit for releasably attaching the apparatus to a medical device or for releasably receiving at least a part of said
medical device, wherein said medical device is for ejecting a medicament and is one of an injection device and an infusion
device, and

one or more optical sensors for determining information related to a condition and/or use of said medical device, wherein
said one or more optical sensors comprise at least one optical sensor configured to capture an image of an information-bearing
or information-displaying part of said medical device, and wherein said apparatus is configured to recognize characters from
said captured image.

US Pat. No. 9,089,645

DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device comprising:
a first dose setting mechanism, wherein the first dose setting mechanism is operably coupled to a primary reservoir holding
a first medicament;

a dose setter operably coupled to the first dose setting mechanism;
a second dose setting mechanism, wherein the second dose setting mechanism is operably coupled to a secondary reservoir holding
a second medicament, wherein the second dose setting mechanism is mechanically linked to the first dose setting mechanism,
wherein the second dose setting mechanism comprises a biasing element,

wherein the biasing element is configured to assist with dispense of the second medicament.

US Pat. No. 9,427,525

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament (M), comprising:
a body arranged to contain a syringe with a hollow injection needle and a stopper for sealing the syringe and displacing the
medicament (M), the body having a distal end (D) and a proximal end (P) with an orifice intended to be applied against an
injection site, wherein the syringe is slidably arranged with respect to the body;

a torsion spring capable of, upon activation:
pushing the needle from a covered position inside the body into an advanced position through the orifice and past the proximal
end (P),

operating the syringe to supply the dose of medicament (M); and
an activating mechanism comprising either a wrap-over trigger sleeve or a trigger button, the activating mechanism arranged
to lock the torsion spring in a pressurized state prior to manual operation and capable of, upon manual operation, releasing
the torsion spring for injection;

wherein the torsion spring is grounded at one end in the body and at the other end in a first gear member rotatable about
a longitudinal axis, wherein the first gear member, upon rotation, is arranged for translating a second gear member toward
the proximal end (P), the second gear member prevented from rotating and arranged to be coupled to the stopper in order to
push it towards the proximal end (P), wherein the first gear member is engaged with the activating mechanism prior to manual
operation in a manner to prevent rotation and disengaged from the activating mechanism upon manual operation;

wherein a ratchet wheel is arranged on the first gear member, the ratchet wheel having a number of circumferentially arranged
teeth, wherein the activating mechanism comprises at least one locking feature for engaging the ratchet wheel in a manner
to prevent rotation and wherein the locking feature is arranged to allow rotation on manual operation.

US Pat. No. 9,364,614

DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. Drug delivery device, comprising:
a drug container, the drug container defining a cavity for containing a drug, wherein a stopper is slidably disposed within
the container so as to displace the drug through a discharge nozzle on translation in a distal direction,

a case for retaining the drug container,
an inner magnet disposable within the drug container for abutting the stopper,
at least one outer magnet disposed within the case coaxially with the container and slidable in an axial direction,
a trigger arrangement for advancing the outer magnet in a distal direction on actuation,
wherein the outer magnet and the inner magnet are arranged for magnetically interacting through the drug container wall such
the outer magnet advances the inner magnet on trigger actuation, characterized in that a cord with a low flexibility is arranged
between a proximal face of the inner magnet and the outer magnet so as to define their relative axial position, and

wherein the cord runs from the inner magnet in the proximal direction through a deviating point in a proximal rear cover of
the case, then back in the distal direction and through another deviating point in a distal front cover and again in the proximal
direction to the outer magnet.

US Pat. No. 9,289,170

APPARATUS FOR ELICITING A BLOOD SAMPLE

SANOFI-AVENTIS DEUTSCHLAN...

1. Apparatus for eliciting a blood sample, the apparatus comprising:
a lancet for lancing a body part of a user; and
a cleaning member of absorbent material operable to clean a surface of the body part, the apparatus being configured such
that in use the lancet is moved to lance a body part of a user and subsequently the cleaning member is moved to contact the
body part of the user so as to remove blood from the surface of the body part prior to collection of the blood sample from
the surface of the body part.

US Pat. No. 9,381,304

CARTRIDGE HOLDER AND ALIGNMENT INTERFACE

SANOFI-AVENTIS DEUTSCHLAN...

1. A system for a drug delivery device comprising:
a reservoir holder configured to hold a reservoir, where the reservoir holder comprises a bore having an inner wall comprising
a ramp profile which comprises a single ramp terminating in an end alignment position, wherein the length of the ramp profile
is equal to the circumference of the reservoir holder;

an alignment interface comprising a main body configured to be coupled to the reservoir and a first alignment feature provided
on the main body configured to engage the ramp as the reservoir is inserted into the bore of the reservoir holder; and

one or more coding features,
wherein, when the alignment interface is inserted into the reservoir holder, the engagement of the first alignment feature
with the ramp of the reservoir holder causes the alignment interface to rotate and thereby align and engage the first alignment
feature with the end alignment position.

US Pat. No. 9,364,519

PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE

SANOFI-AVENTIS DEUTSCHLAN...

1. A method for treating Alzheimer's disease in a patient in need thereof, comprising administering to said patient a therapeutically
effective amount of a pharmaceutical composition comprising desPro36-Exendin-4(1-39)Lys6-NH2 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, auxiliary substance,
or a combination thereof.

US Pat. No. 9,427,527

FIXED-DOSE MEDICAMENT DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A medicament delivery device comprising:
a housing;
a safety sleeve movable between an extended position and a retracted position relative to the housing;
a guide sleeve rotatably disposed in the housing, the guide sleeve comprising at least one guide pin adapted to engage one
or more of a plurality of ribs on the safety sleeve when the safety sleeve is in the extended position;

a plunger slidably disposed in the safety sleeve; and
a button coupled to the housing, the button comprising one or more projections adapted to engage the at least one guide pin
of the guide sleeve such that the guide sleeve rotates relative to the safety sleeve upon translation of the button relative
to the housing when the safety sleeve is in the retracted position,

wherein rotation of the guide sleeve relative to the safety sleeve allows the plunger to translate a predetermined axial distance
relative to the safety sleeve.

US Pat. No. 9,364,616

DRIVE MECHANISM OF A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism of a drug delivery device, comprising:
a piston rod extending in an axial direction to be operably engaged with a piston of a cartridge, the piston rod being adapted
to exert distally directed pressure to the piston for expelling a liquid medicament from the cartridge,

a housing component to accommodate the piston rod and having a guiding member extending in a lateral plane and being engaged
with the piston rod for guiding the piston rod in the axial direction relative to the housing component, wherein the piston
rod comprises an outer thread, and the guiding member and the piston rod are threadedly engaged such that the piston rod is
rotatably supported in the housing component, and

at least one actuation lock to engage with the piston rod to inhibit a proximally directed movement of the piston rod relative
to the housing component,

wherein the piston rod further comprises at least one radially inwardly extending recess to mate with at least one radially
inwardly extending stop element of the actuation lock, and

wherein the guiding member comprises multiple stop elements arranged along the circumference of the piston rod.

US Pat. No. 9,174,000

DRUG DELIVERY DEVICE WITH BIODEGRADABLE PLASTIC COMPONENTS

Sanofi-Aventis Deutschlan...

1. A user operated pen-type injector for dispensing a user settable amount of a medicinal product, comprising:
a cartridge holder configured to receive and hold a product-containing cartridge,
the cartridge mountable in the cartridge holder and comprising a piston slidably arranged therein,
at least one housing component operably coupled to the cartridge holder,
a drive mechanism component operably engageable with the piston of the cartridge for dispensing a user settable dose of the
medicinal product,

wherein at least one of the cartridge holder, the cartridge, the at least one housing component, and the drive mechanism at
least partially comprises a plastic material comprising a substantially non-biodegradable polymer as a base material and at
least one additive, the at least one additive adapted to induce or to trigger a degradation process of the base material,

wherein the at least one additive comprises at least one kind of metal ions and a catalyst for splitting of molecular chains
of the substantially non-biodegradable polymer in response to an exposure to at least one of electromagnetic radiation, heat,
moisture, and a microbial environment,

wherein the at least one additive renders at least one of the cartridge holder, the cartridge, the at least one housing component,
and the drive mechanism biodegradable thereby forming an at least one biodegradable component, and

wherein the degradation process does not start until the at least one biodegradable component is exposed to at least one of
electromagnetic radiation, heat, moisture, and the microbial environment.

US Pat. No. 9,320,857

NEEDLE SAFETY DEVICE

Sanofi-Aventis Deutschlan...

1. A needle safety device comprising:
a needle hub adapted to couple to an injection device;
a needle coupled to the needle hub, the needle having a distal tip;
a needle shield telescopically coupled to the needle hub with a biasing element coupled to a distal portion of the needle
shield; and

a locking element arranged on the needle hub,
wherein, when the needle shield is in a first axial position, the needle shield covers the distal tip of the needle,
wherein, when the needle shield is in a second axial position, the needle shield moves proximally relative to the needle hub
to expose the distal tip of the needle and the locking element directly deflects the biasing element, and

wherein, when the needle shield is in a third axial position, the locking element engages the biasing element and the needle
shield covers the distal tip of the needle.

US Pat. No. 9,238,107

MEDICATED MODULE WITH BYPASS AND NEEDLE GUARD

SANOFI-AVENTIS DEUTSCHLAN...

1. A medicated module attachable to a drug delivery device containing a primary reservoir with a first medicament, said medicated
module comprising:
a connecting body configured for attachment to said drug delivery device;
a proximal first needle fixed within said medicated module;
a distal second needle fixed within said medicated module;
a bypass component moveable between a first position and a second position;
a needle guard operatively coupled to said medicated module;
a biasing element positioned to bias said needle guard; and
a secondary reservoir containing at least one dose of a second medicament and configured for fluid communication with said
first and second needle,

wherein said bypass component defines a cavity that retains said secondary reservoir,
wherein said bypass component comprises at least one bypass vane,
wherein in said first position, said bypass component is configured to allow said first medicament from said drug delivery
device to bypass said secondary reservoir and exit said second needle while said second needle is in fluid engagement with
said first needle, and

wherein in said second position, said bypass component provides a fluid connection between said first needle, said secondary
reservoir, and said second needle.

US Pat. No. 9,089,651

DOSE SETTING MECHANISM

SANOFI-AVENTIS DEUTSCHLAN...

1. A dose setting mechanism for a drug delivery device, the mechanism comprising:
a drug delivery device housing;
a dose dial component positioned at least partly in the housing and rotatable during a dose setting step;
a drive sleeve positioned within the dose dial component;
a spindle positioned within the drive sleeve;
a clutch positioned between the dose dial component and the drive sleeve; and
a clutch ring rotationally fixed relative to the housing when a dose less than the minimum allowable dose is selected,
wherein, when the dose dial component is rotated to select a dose less than a minimum dose, the clutch ring prevents the drive
sleeve from rotating, causing the spindle to be disengaged from the drive sleeve, thereby preventing the selected dose from
being administered.

US Pat. No. 9,353,170

LONG-ACTING TRANSIENT POLYMER CONJUGATES OF EXENDIN

SANOFI-AVENTIS DEUTSCHLAN...

1. A polymeric compound of the general formula (I)
Pol-L-E  (I)
wherein Pol is a polymer,
wherein L is a releasing linker capable of undergoing autohydrolysis and is a non-biologically active linker moiety -L1 represented by formula (Ia),


wherein the dashed line indicates attachment to a nitrogen atom of a biologically active moiety by forming an amide bond,
wherein R is substituted with one group L2-Pol,

wherein L2 is a single chemical bond or a spacer,

wherein E is exendin or an exendin agonist,
and wherein the bond between L and E is hydrolysed under in vivo conditions at a pH-value between 7.0 and 7.5 at a temperature
of 36° to 38° C. in human plasma with a half-life of 24 hours or more.

US Pat. No. 9,333,303

DRUG DELIVERY DEVICE HAVING A TRIGGER

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device to deliver two or more medicaments comprising:
a variable dose setting mechanism, wherein the variable dose setting mechanism is operably coupled to a primary reservoir
holding a first medicament;

a fixed dose setting mechanism, wherein the fixed dose setting mechanism is operably coupled to a secondary reservoir holding
a second medicament, wherein the fixed dose setting mechanism comprises a trigger biasing member;

a single dose setter operably coupled to the variable dose setting mechanism for setting a variable dose of the first medicament;
a mechanical coupling, wherein the mechanical coupling operably couples the variable dose setting mechanism and the fixed
dose setting mechanism such that

during dose setting, activation of the single dose setter sets a variable dose of the first medicament and thereby automatically
sets a fixed dose of the second medicament, and

wherein, during dispense, the trigger biasing member at least assists with the dispense of the fixed dose of the second medicament.

US Pat. No. 9,283,328

NEEDLE ASSEMBLY ATTACHMENT AND REMOVAL DEVICE

Sanofi-Aventis Deutschlan...

1. A needle assembly attachment and removal device comprising:
a base;
an outer member fixed to the base, an inner surface of the outer member having first threads;
a first inner member telescoped in the outer member and having pins adapted to engage the first threads, wherein the first
inner member is adapted to hold a needle assembly; and

a second inner member disposed in the outer member and adapted to receive the first inner member, an inner surface of the
second inner member having second threads adapted to engage the pins,

wherein axial movement of the first inner member within the outer member causes rotation of the first inner member and the
needle assembly relative to the outer member.

US Pat. No. 9,242,051

NEEDLE ASSEMBLY FOR DRUG DELIVERY DEVICES

Sanofi-Aventis Deutschlan...

1. A needle assembly for a drug delivery device comprising:
a cup-shaped receptacle having a bottom section supporting a needle element being adapted to penetrate a pierceable seal of
a cartridge to be disposed in a cartridge holder of the drug delivery device,

wherein the receptacle comprises a sidewall having an oval cross-section, the sidewall comprising two radially inwardly protruding
latching elements adapted to engage with two radially outwardly extending ribs of a support section of the cartridge holder
for releasably fastening the needle assembly to the cartridge holder, the support section of the cartridge holder comprising
an oval cross-section smaller than the receptacle,

wherein the ribs are arranged on opposite endpoints of a long axis of the oval cross-section of the support section, and the
latching elements are arranged on opposite endpoints of a long axis of the oval cross-section of the sidewall, and

wherein the latching elements and the ribs are convertible into a release configuration by changing a distance between the
latching elements and the ribs through twisting the receptacle with respect to the support section.

US Pat. No. 9,238,106

DOSE SETTING MECHANISM FOR PRIMING A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A dose setting mechanism for a drug delivery device comprising:
a dial sleeve;
a nut; and
an inner body,
wherein the dial sleeve is coupled to the nut that is threadedly engaged to the inner body, where the dial sleeve and nut
are coupled to prevent relative rotational movement between the dose dial sleeve and the nut while allowing relative axial
movement during priming,

wherein the dial sleeve moves axially relative to the nut during priming of the drug delivery device from a first axial position
to a second axial position where the dial sleeve irreversibly engages the nut, and

wherein the dial sleeve translates along a helical path during dose setting of the drug delivery device.

US Pat. No. 9,155,837

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament (M), comprising an elongate housing, a syringe and a trigger
button, wherein an interlock mechanism is provided for defining an operation sequence of the auto-injector in a manner to
allow the trigger button to be operated only when a proximal end (P) of the auto-injector is pressed against an injection
site, wherein a detector means is arranged inside the elongate housing at the proximal end (P), the detector means slidable
in longitudinal direction and biased by a detector spring into a position with the detector means protruding beyond the proximal
end (P), wherein a dog is arranged at the trigger button and wherein at least one longitudinal bar is provided, at least one
of the bars slidable in longitudinal direction and coupled to the detector means for joint movement at least in distal direction
(D), wherein a recess for the dog is provided in the bar for allowing the trigger button to be pressed when the detector means
is being pushed into the auto-injector and wherein otherwise the dog is engaged with the bar in a manner to prevent the trigger
button from being pressed, wherein a loading bay is arranged slidable in longitudinal direction in the auto-injector in a
manner to advance or retract the syringe, characterized in that at least one of the bars comprises a dog protruding from the
bar wherein a syringe latch arm having a distal end and a proximal end is pivoted about a latch arm axis transversally arranged
to and offset from a longitudinal axis of the auto-injector, wherein the distal end of the latch arm is arranged for engaging
behind a shoulder arranged at the loading bay in a manner to prevent the loading bay from being moved in proximal direction
(P) and wherein the proximal end of the latch arm is arranged for being engaged by the dog when the detector means is pushed
into the auto-injector thus disengaging the distal end of the latch arm from the shoulder, the auto-injector further comprising:
the elongate housing arranged to contain the syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), the housing having a distal end (D) and a proximal end (P) with an orifice intended to be applied against
an injection site, wherein the syringe is slidably arranged with respect to the housing,
a drive spring capable of, upon activation:
pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal
end (P), and

operating the syringe to supply the dose of medicament (M), andan activating means arranged to lock the drive spring in a compressed state prior to manual operation and capable of, upon
manual operation, releasing the drive spring for injection, the elongate housing comprising a distal portion and a proximal
portion connected by a hinge, the portions rotatable about the hinge relative to each other between an aligned position and
a maximum opening angle, wherein the drive spring is compressed by rotating the portions out of the aligned position towards
the maximum opening angle, wherein the activating means are arranged to lock the drive spring in the compressed state when
the portions are rotated at least almost to the maximum opening angle and wherein the loading bay for holding the syringe
is arranged in the proximal portion, the loading bay being accessible from its distal end for loading or unloading the syringe
when the portions are rotated out of the aligned position,characterized in that a lever is attached with one end to a fixed first pivot in the proximal portion, wherein the other end
of the lever is attached to a second pivot arranged at a sliding shuttle in the distal portion, the sliding shuttle translatable
in longitudinal direction of the distal portion between a maximum proximal position when the portions are aligned and a maximum
distal position when the portions are rotated at least almost by the maximum opening angle, wherein a drive collar arranged
at a proximal end of the drive spring is engageable by the sliding shuttle in order to compress the drive spring.

US Pat. No. 9,358,340

METHOD AND ASSEMBLY FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A method for securing a cartridge in a cartridge holder of a drug delivery device, wherein the drug delivery device is
configured to dispense at least one dose of a drug, the method comprising the following steps:
providing the cartridge comprising a piston, wherein a distal portion of the cartridge comprises an outwardly directed shoulder
portion,

inserting the cartridge into the cartridge holder, the cartridge holder comprising a proximal end and a distal end, wherein
a distal portion of the cartridge holder comprises an inwardly directed flange portion,

the shoulder portion of the cartridge being suitable dimension to abut the flange portion of the cartridge holder,
prior to dose dispense, utilizing an adjusting member to axially displace the cartridge in a proximal direction with respect
to the cartridge holder from a distal initial position to a proximal end position, so as to reduce a gap between a piston
rod and the piston of the cartridge,

utilizing the adjusting member to secure the cartridge in the proximal end position against displacement in a distal direction
with respect to the cartridge holder, and

preventing an abutment of the shoulder portion of the cartridge and the flange portion of the cartridge holder,
wherein the adjusting member is used for securing the cartridge in the cartridge holder and wherein securing the cartridge
in the cartridge holder comprises securing the adjusting member against displacement with respect to the cartridge holder
in the distal direction when the cartridge is in the proximal end position, and

wherein the adjusting member extends from an inside of the cartridge holder to an outside of the cartridge holder, wherein
an outer surface of the adjusting member accessible from the outside of the cartridge holder is provided for attaching a needle
unit to the adjusting member.

US Pat. No. 9,358,351

GEARBOX

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament (M), the auto-injector having a distal end (P) and a proximal
end (D) with an orifice to be applied against an injection site and comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), wherein the syringe is slidably arranged with respect to the housing;

a drive spring capable of, upon activation:
pushing the needle from a retracted position into an advanced position through the orifice and past the proximal end (P),
and

operating the syringe to supply the dose of medicament (M), wherein a shroud is arranged at least partially inside the housing,
the shroud slidable in longitudinal direction between at least a retracted position, in which the needle is exposable and
an advanced position, in which the needle is covered by the shroud, wherein the shroud is arranged to be locked in the retracted
position prior to manual operation of the drive collar and wherein the shroud is arranged to be pushed towards the advanced
position by a syringe spring when the drive spring has been released, wherein the shroud is slidable from the retracted position
in distal direction (D) into an unlocking position by a small distance against the bias of at least one flexural element,
wherein a plurality of protrusions are arranged to allow the drive collar to be operated only, when the shroud is in the unlocking
position, wherein the a plurality of protrusions are arranged to prevent the drive collar from being operated otherwise

a drive collar arranged to lock the drive spring in a compressed state prior to manual operation and capable of, upon manual
operation, releasing the drive spring for injection, and

a gearbox arranged between the drive spring and the syringe or the stopper.

US Pat. No. 9,295,784

MEDICAMENT DELIVERY DEVICE WITH CAP

Sanofi-Aventis Deutschlan...

1. A hand-held medicament delivery device comprising:
a housing containing a first electrical circuit and a battery,
a medicament delivery mechanism, and
a protective cap releasably securable to the housing, wherein the protective cap comprises a switch actuator, wherein the
switch actuator is a magnetic component configured to activate a contactless switch,

wherein the housing includes a contactless switch and the cap switch actuator configured to activate the contactless switch
in response to the magnetic component of the protective cap being in proximity to the contactless switch, and wherein the
switch is operable between an on state in which the first electrical circuit is connected to the battery and an off state
in which the first electrical circuit is disconnected from the battery, wherein the first electrical circuit comprises a display
and a user button.

US Pat. No. 9,265,891

ASSEMBLY OF A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. An assembly of a drug delivery device with a longitudinal axis, comprising:
a body comprising a proximal end and a distal end,
a drive assembly comprising a piston rod and a drive sleeve and being at least partially arranged within the body and being
adapted to facilitate dispense of a medicinal product,

a first button member acting on the drive assembly to prepare the drug delivery device in the form of priming and/or mixing
powder with a fluid and/or expelling a priming portion of the medicinal product or air during a pre-ready state and a transient
state of the assembly for dispensing the medicinal product during a ready state of the assembly,

a second button member acting on the drive assembly to dispense the medicinal product in the ready state, wherein the second
button member is inaccessible as long as the preparation of the drug delivery device is uncompleted,

wherein first button member encases the second button member at least partially to render it inaccessible as long as the preparation
of the drug delivery device is uncompleted,

wherein the first button member acting on the drive assembly to prepare the drug delivery device results in movement of a
piston rod and/or the drive sleeve to prepare the drug delivery device,

wherein the ready state chronologically follows the preparation during the pre-ready state and the transient state of the
assembly, and

wherein the first button member is adapted to be detachable From the body (i) after the preparation of the drug delivery device
is completed and (ii) before dispensing of the medicinal product.

US Pat. No. 9,242,047

DETENT MECHANISM

Sanofi-Aventis Deutschlan...

1. A detent mechanism for controlling translation between two components in a longitudinal direction, the detent mechanism
comprising:
a resilient beam on one of the components; and
a rhomboid ramp member on the other component, the rhomboid ramp member comprising a first ramp and a second ramp, wherein
each ramp resides on one longitudinal side of the rhomboid ramp member,

the rhomboid ramp member further comprising a first transversal side and a second transversal side,
the resilient beam being essentially straight when relaxed and having a first beam head and arranged to interact in a ramped
engagement with respectively one of two ramps in such a manner that application of a translative force between the components
in one longitudinal direction with the first beam head engaged to the first ramp of the rhomboid ramp member in a first state
deflects the resilient beam in one transversal direction when a predetermined value of the translative force, at least depending
on a resilience of the resilient beam, is overcome so as to allow the first beam head to travel along the first transversal
side of the rhomboid ramp member on continued relative translation of the components,

wherein the resilient beam is allowed to relax when the first beam head has reached the second ramp of the rhomboid member
in a second state,

wherein application of a translative force between the components in the other longitudinal direction with the first beam
head engaged to the second ramp of the rhomboid member deflects the resilient beam in the other transversal direction when
a predetermined value of the translative force, at least depending on the resilience of the resilient beam, is overcome so
as to allow the first beam head to travel along the second transversal side of the rhomboid ramp member on continued relative
translation of the components.

US Pat. No. 9,199,040

DRUG DELIVERY DEVICE LAST DOSE LOCK-OUT MECHANISM

Sanofi-Aventis Deutschlan...

1. A dose setting mechanism for a drug delivery device, wherein the dose setting mechanism is operable to be coupled to a
cartridge housing of the drug delivery device configured to house a cartridge of medication, the dose setting mechanism comprising:
a last dose lock-out mechanism preventing a user of said dose setting mechanism from setting a dose of said medication that
is greater than said medication in said cartridge, said lock-out mechanism comprising:

a dose setting mechanism housing;
a rotatable shaft;
a helical groove having a first pitch provided along a first portion of said rotatable shaft and a second pitch provided along
a second portion of said rotatable shaft, said first pitch different from said second pitch; and

a non-rotating member disposed between said dose setting mechanism housing and said helical groove of said shaft,
wherein during dose setting of said drug delivery device, said shaft is rotated relative to said non-rotating member and moves
axially with respect to said dose setting mechanism housing, while said non-rotating member traverses along said groove from
a first end of said shaft towards a second end of said shaft,

wherein said non-rotating member traverses along said groove until a dose greater than said medication remaining in said cartridge
is selected and said non-rotating member prevents said shaft from rotating and increasing said dose, and

wherein said non-rotating member comprises at least one substantially radial stop face, said at least one substantially radial
stop face engaging at least one stop face on said rotatable shaft so that said non-rotating member prevents said shaft from
rotating.

US Pat. No. 9,089,648

MEDICATED MODULE WITH PREMIX MEDICAMENT

Sanofi-Aventis Deutschlan...

1. A medicated module attachable to a drug delivery device with a primary reservoir containing a first drug agent, comprising,
a. a housing having a proximal end and a distal end, where the proximal end has a connector configured for attachment to a
drug delivery device; and

b. a secondary reservoir containing at least one dose of a premixed medicament, wherein at a point in time before the primary
reservoir is fluidly connected to the second reservoir, a second drug agent contained in the premixed medicament is the same
or an equivalent of the first drug agent contained in a primary reservoir of the drug delivery device.

US Pat. No. 9,408,893

PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS

Sanofi-Aventis Deutschlan...

1. A method for improvement of glycemic control in a patient having diabetes type 2, comprising administering to the patient
a therapeutically effective amount of the pharmaceutical combination comprising:
(a) desPro36Exendin-4(1-39)-Lys6-NH2 and/or a pharmaceutically acceptable salt thereof, and

(b) a glitazone and/or a pharmaceutically acceptable salt thereof; and
wherein the patient has a haemoglobin A1c (HbA1c) value of at least 8% and a fasting plasma glucose of at least 9 mmol/L when treated with glitazone alone.

US Pat. No. 9,365,306

PACKAGING SYSTEM FOR MULTI-COMPONENT MEDICAL PRODUCTS

SANOFI-AVENTIS DEUTSCHLAN...

1. A method of assembling multi-component medical products using sterile tray grids comprising the steps of:
a. providing a packaging system comprising a sterile tray grid of at least two connected receptacles, wherein each receptacle
is connected to an adjacent receptacle through a strike line which is configured to allow the receptacles to be removed and
separated from one another, wherein each receptacle has a top sealing surface and an internal chamber having a centering member
configured to support a first sub-assembly of a multi-component medical product, wherein the first sub-assembly is positioned
on the centering member thereby fixing the first sub-assembly against rotational movement, and, wherein the packaging system
is entirely contained within a first seal;

b. removing the first seal in a sterile environment;
c. connecting a second sub-assembly to the first sub-assembly to form a finished multi-component medical product while the
centering member is holding the first sub-assembly in a predefined vertical position; and

d. attaching a second seal to each of the top sealing surfaces of each receptacle to form a finished sterile tray grid of
sealed receptacles, where each respective receptacle contains a respective multi-component medical product.

US Pat. No. 9,283,326

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

16. Auto-injector for administering a dose of a liquid medicament (M), comprising:
a tubular chassis,
a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis and partially arranged in the
chassis, the carrier containing a syringe with a hollow injection needle, a drive spring and a plunger for forwarding load
of the drive spring to a stopper of the syringe, wherein the syringe is locked for joint axial translation with the carrier,

a wrap-over trigger sleeve arranged over the distal end (D) of the auto-injector, the trigger sleeve extending at least almost
over the whole length of the auto-injector, wherein translation of the trigger sleeve relative to the chassis triggers needle
insertion when an end face of the trigger sleeve contacts with an end face of the carrier,

a control spring arranged around the carrier, wherein the control spring is configured to insert the needle and to retract
the needle after administering the dose of the liquid medicament (M),

a first interlock configured to couple a proximal end of the control spring to either the carrier for advancing it for needle
insertion or to the chassis for needle retraction depending on the relative axial position of the carrier and the trigger
sleeve,

wherein the first interlock comprises a proximal collar for transmitting load of the proximal end of the control spring, the
proximal collar arranged to be engaged on a thread on the carrier in an initial state, the proximal collar having a pin arranged
to be splined to a first longitudinal groove in the trigger sleeve in the initial state so as to prevent rotation of the proximal
collar and couple it to the carrier, wherein the first longitudinal groove is arranged to release the pin upon translation
of the chassis and carrier in proximal direction (P) under load of the control spring when the auto- injector is removed from
the injection site thereby allowing rotation and translation of the proximal collar relative to the carrier under load of
the control spring and subsequent abutting of the proximal collar against the chassis,

a second interlock configured to release the drive spring for injection when the carrier reaches an injection depth during
needle insertion,

a third interlock configured to couple the chassis to the carrier for joint axial translation relative to the trigger sleeve,
wherein the third interlock is arranged to decouple the chassis from the carrier upon translation of the trigger sleeve in
proximal direction (P) relative to the chassis thus releasing the control spring for needle insertion,

a fourth interlock configured to couple a distal end of the control spring to either the carrier for needle retraction or
to the trigger sleeve otherwise.

US Pat. No. 9,089,656

SPINDLE AND BEARING COMBINATION AND DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A spindle and bearing combination for use in a drug delivery device comprising a cartridge, the combination comprising,
a spindle having a distal end; and
a disk-shaped bearing adapted to abut a piston in the cartridge, the bearing comprising a first connection and a second connection
to the distal end of the spindle, and wherein the bearing and spindle are formed as one unitary part,

where the first connection comprises a web that fixedly attaches the bearing to the spindle to prevent independent movement
of the bearing relative to the spindle and

where the second connection is created and replaces the first connection when the web is sheared and disconnected from the
bearing,

and wherein the second connection comprises a joint that allows the spindle to rotate relative to the bearing.

US Pat. No. 9,339,607

MEDICAMENT DELIVERY DEVICES

Sanofi-Aventis Deutschlan...

1. A medicament delivery device comprising: a housing for holding a medicament cartridge, the medicament cartridge having
a medicament outlet and a bung moveable axially along the medicament cartridge for dispensing a medicament;
a piston rod having a plunger for moving the bung, and a lead member telescopically coupled to the plunger;
a battery powered drive for telescopically extending or retracting the piston rod; and
a linkage coupled between the plunger and
an anchorage
wherein
the medicament delivery device includes
a drive member telescopically coupled to the lead member,
wherein the battery powered drive is operative to rotate the drive member to telescopically move the lead member relative
to the drive member

whereby the plunger is moved relative to the lead member by way of the linkage
wherein the linkage is an elongate element acting between the housing and the plunger via a pulley, and
wherein the pulley is a wheel located on the lead member.

US Pat. No. 9,067,024

SAFETY DEVICE FOR A PRE-FILLED SYRINGE AND INJECTION DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A safety device for a pre-filled syringe, comprising
a hollow support body to retain the pre-filled syringe therein,
a retaining collar releasably mounted to the support body and
a rotating collar comprising a central opening for the reception of the prefilled syringe and at least one outwardly protruding
guide pin that protrudes through a guide track formed into the support body,

a guide rail formed into an inner surface of an outer body,
whereas the guide track comprises an inclined section and an axial section connected therewith,
whereas the rotating collar is arranged within the support body and slidable along an axial length of the support body and
rotatable around a central axis of the safety device and whereas the retaining collar is movable with respect to the support
body in a proximal direction when the retaining collar is released from being mounted to the support body by the rotating
collar.

US Pat. No. 9,216,231

STERILIZATION APPARATUS AND METHOD FOR CONTROLLING OF A STERILIZATION APPARATUS

Sanofi-Aventis Deutschlan...

1. Sterilization apparatus for the sterilization of an object by a gaseous or liquid fluid comprising:
a sterilization chamber in which the object is positioned,
a filter chamber comprising a cone-formed inlet and a filter seat,
at least an acceleration device for accelerating the fluid to a predetermined flow-speed, wherein the acceleration device
is positioned on the cone-formed inlet,

at least a filter device for separating particles from the fluid, wherein the filter device is positioned in the filter seat,
at least an orifice device having a plurality of openings being arranged in a flow-path of the fluid, and
first and second pressure sensors disposed upstream and downstream of the orifice device, respectively, wherein the first
pressure sensor is disposed downstream of the filter device and wherein the second pressure sensor is disposed upstream of
the at least one object to be sterilized.

US Pat. No. 9,084,852

PISTON ROD ASSEMBLY FOR A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A piston rod assembly for a drug delivery device, comprising: a piston rod adapted to be operably engaged with a piston
of a cartridge containing a medicament, at least one adjusting member displaceably disposed at the piston rod with respect
to the piston rod's long axis, and being interconnected with a distal end section of the piston rod, and at least one interlock
means adapted to interact with the adjusting member and with the piston rod for mutually locking in position the adjusting
member and the piston rod in an arbitrary relative position and wherein the adjusting member and the piston rod are threadedly
engaged in order to axially displace the piston rod and the adjusting member relative to each other, and wherein the interlock
means is inhibits self-acting relative rotation between the piston rod and the adjusting member, wherein the interlock means
comprise at least one resiliently biased tongue member adapted to engage with a corrugated outer surface portion of the adjusting
member or of the piston rod.

US Pat. No. 9,283,327

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament (M), comprising:
a substantially cylindrical housing arranged to contain a pre-filled syringe,
a syringe retainer slidably arranged with respect to the housing that mounts a pre-filled syringe with an injection needle,
a plunger and a stopper for sealing a syringe barrel,

a coupling shroud slidably arranged within the housing and releasably coupled to the plunger and
a single drive means capable of, upon release:
driving the coupling shroud from a first position (I) in the proximal direction (P), wherein the proximal translatory movement
of the coupling shroud with respect to the housing,

translates the syringe retainer in the proximal direction (P) to expose the injection needle of the pre-filled syringe,
depresses the plunger connected to the stopper into the syringe barrel to expel the dose of medicament (M) and
advances a needle shroud to a safe position (PS) to surround the injection needle after the medicament (M) has been at least
partially delivered,

wherein the coupling shroud is decoupled from the plunger at a pre-determined second position (II) defined by an aperture
formed into the housing,

wherein a coupling catch is arranged to abut against a shoulder formed to the plunger to releasably couple the plunger to
the coupling shroud.

US Pat. No. 9,457,142

DEVICE AND METHOD FOR DELIVERY OF TWO OR MORE DRUG AGENTS

SANOFI-AVENTIS DEUTSCHLAN...

1. A device comprising:
an electro-mechanical drive system operative to expel:
a dose of primary medicament from a primary reservoir containing the primary medicament; and,
a dose of fluid agent from a secondary reservoir containing the fluid agent, where the fluid agent is not the primary medicament;
a dispense assembly in fluid communication with both the primary and secondary reservoirs; and
a control unit operably coupled to the electro-mechanical drive system and configured to first receive information on a dose
of the primary medicament,

wherein said control unit after receiving the information on the dose of primary medicament determines at least one value
of the dose of a fluid agent based at least in part on said dose of said primary medicament and a therapeutic dose profile,
where the therapeutic dose profile is predetermined and programmed within the device,

wherein the therapeutic dose profile is a non-linear profile of the primary medicament and the fluid agent;
wherein the control unit is configured to activate the electro-mechanical drive system to expel:
the at least one value of a dose of the fluid agent from the secondary reservoir; and,
the said dose of primary medicament from the primary reservoir;
such that the at least one value of the dose of the fluid agent and the dose of primary medicament are both dispensed through
the dispense assembly.

US Pat. No. 9,352,101

SAFETY DEVICE FOR A PRE-FILLED SYRINGE AND AN INJECTION DEVICE

Sanofi-Aventis Deutschlan...

1. A safety device for a pre-filled syringe with an injection needle comprising
a support body adapted to mount the pre-filled syringe,
a needle shield slidably arranged with respect to the support body,
a retention and locking mechanism (M) configured to retain and lock the needle shield with respect to the support body in
a first and a second advanced position (PA1, P A2) and in a retracted position (PR),

wherein the needle shield comprises an annular flange adapted to rest on the skin of the patient receiving an injection and
wherein the retention and locking mechanism (M) are arranged at a distal end of the safety device, and

wherein the needle shield is movable from the first advanced position (PA1) to the retracted position (PR) and further to the second advanced position (PA2), wherein the needle shield in the first advanced position (PAI) protrudes the support body in the distal direction by a
first distance (D1) and the needle shield in the second advanced position (PA2) protrudes the support body in the distal direction by a second distance (D2), wherein the first distance (D1) is smaller than the second distance (D2).

US Pat. No. 9,364,617

MEDICAMENT DELIVERY DEVICE AND ACTUATION MECHANISM FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. An actuation mechanism for a medicament delivery device having a needle with a distal tip, the actuation mechanism comprising:
an outer sleeve telescopically arranged relative to the delivery device, the outer sleeve axially translatable relative to
the delivery device;

an inner sleeve telescopically arranged relative to the outer sleeve, the inner sleeve axially translatable relative to the
outer sleeve;

a first spring element biasing the inner sleeve in a distal direction relative to the outer sleeve; and
a second spring element biasing the outer sleeve in the distal direction relative to the delivery device;
wherein, in a first state, the inner sleeve protrudes distally from the outer sleeve and the outer sleeve protrudes distally
from the delivery device,

wherein, in a second state, the inner sleeve is contained within the outer sleeve, and
wherein movement of the outer sleeve proximally relative to the delivery device in the second state initiates delivery of
a medicament in the delivery device.

US Pat. No. 9,233,215

AUTO-INJECTOR WITH INJECTION DAMPER

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament, comprising:
an elongate main body arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament, the main body having a distal end and a proximal end with an orifice intended to be applied against an injection
site, wherein the syringe is slidably arranged with respect to the main body,

a spring capable of, upon activation:
pushing the needle from a covered position inside the main body into an advanced position through the orifice and past the
proximal end,

operating the syringe to supply the dose of medicament, and
retracting the syringe with the needle into the covered position after delivering the medicament,
a trigger arranged to lock the spring in a pressurized state prior to manual operation and capable of, upon manual operation,
releasing the spring for injection,

wherein the spring comprises a single drive spring in the shape of a compression spring arranged to be grounded at a distal
end in the main body for advancing the needle and for injecting the dose of medicament via a plunger and

wherein the drive spring is arranged to have its ground in the main body switched to its proximal end for retracting the syringe,
further comprises a damper arranged around the plunger,
wherein the damper is engaged with the plunger by a spline
so as to cause rotation of either the plunger or the damper at least during part of a translation of the plunger in proximal
direction and share the load of the drive spring between the translation and the rotation.

US Pat. No. 9,149,580

CARTRIDGE HOLDER FOR A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A cartridge holder for a drug delivery device, comprising:
a housing extending in an axial direction and being adapted to receive a cartridge at least partially filled with a medicament,
said cartridge being sealed near a distal end by way of a pierceable seal,

at least one bearing element fixed to the housing, and
at least one tensioning member to engage with the bearing element and with the cartridge in an axial direction for transmitting
a distally directed injection force from the cartridge to the housing.

US Pat. No. 9,446,202

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND RESILIENT ELEMENT FOR A DRIVE MECHANISM

Sanofi-Aventis Deutschlan...

1. A drive mechanism for a drug delivery device, comprising:
a body having a distal end and a proximal end, which are spaced apart in the direction of an axis,
a plunger arranged within the body, the plunger having a first engaging portion and a second engaging portion, the first engaging
portion including a plurality of protruding elements, the second engaging portion including a sawtooth structure,

a lever arranged within the body, the lever having a first pivot that is stationary with respect to the body in the direction
of the axis, a second pivot, and a third pivot formed by an engaging element of the lever,

wherein the first, second, and third pivots are arranged such that a rotation of the lever with respect to the first pivot
moves the second pivot and the third pivot in a same direction with respect to the axis,

wherein the engaging element and the first engaging portion are shaped such that the lever is disengaged from the plunger
when the second pivot is moved relatively to the plunger in a proximal direction toward the proximal end, and the plunger
is engaged with the lever when the second pivot is moved in a distal direction toward the distal end, and

a first resilient element having a cantilever portion, the cantilever portion including a hook having a sloping profile, wherein
the cantilever portion engages the lever to bias the engaging element towards engagement with the first engaging portion,
and

wherein the hook of the first resilient element engages with a sawtooth of the sawtooth structure, thus inhibiting the plunger
from moving in the proximal direction,

wherein the first resilient element is configured to disengage from the second engaging portion, by deflecting the cantilever
portion such that the sloping profile slides over the sawtooth, when the plunger is moved in the distal direction, and

wherein the first resilient element is engaged with the second engaging portion when the second pivot is moved in the proximal
direction.

US Pat. No. 9,351,680

METHOD AND APPARATUS FOR A VARIABLE USER INTERFACE

SANOFI-AVENTIS DEUTSCHLAN...

1. An analyte measurement device comprising:
a housing;
a plurality of penetrating members positionable in the housing;
a penetrating member driver configured to be coupled to penetrating members;
a processor configured to modify a user profile and modulate power from a power supply to the penetrating member driver through
an amplifier;

a visual display on said housing, said visual display having at least one visual indicator positioned next to a corresponding
marking on the housing, the display configured to be customized based on a user's condition and include an indicator of a
number of penetrating members available for use; and

wherein the device is configured to receive telephone calls.

US Pat. No. 9,242,048

MEDICATION DELIVERY DEVICE AND METHOD FOR DISPENSING A MEDICATION

Sanofi-Aventis Deutschlan...

1. A medication delivery device, comprising:
a container for holding a medication in a medication region, the container having a proximal end and a distal end,
a piston which is at least partly arranged within the container and which is displaceable with respect to the container in
the distal direction for dispensing a dose of the medication from the container, and

a seal, wherein
during dispense of the dose of the medication from the container, the piston is at least partly arranged at a distance from
an inner surface of the container, thereby providing a channel between the piston and the container, the channel extending
along a side surface of the piston and being in fluid communication with the medication region, and a length of the channel
increases when the piston is displaced in the distal direction with respect to the seal,

the seal is arranged to limit the channel proximally, and
the piston is displaceable in the distal direction with respect to the seal, wherein the seal is secured against movement
with respect to the container.

US Pat. No. 9,227,015

SPRING DRIVEN INJECTION DEVICE WITH TWIN CARTRIDGES

Sanofi-Aventis Deutschlan...

1. An injection device comprising,
a dose setting and injecting assembly comprising,
i. two sets of dose setting and injecting components configured so that each set of components can operate independently during
dose setting and both sets of components can operate simultaneously during dose injecting, where each set of components comprises
a spring, a plunger, a drive shaft, and a gear;

ii. a single trigger connected to one or more of the dose setting and injecting components such that when the trigger is activated
the spring provides energy to drive the plunger, wherein the trigger comprises teeth that are in direct connection with both
gears when the trigger is in a dose setting position and are disconnected from both gears when the trigger is activated to
a dose injecting position.

US Pat. No. 9,180,258

AUTOINJECTOR

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament (M), comprising
an elongate tubular housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), the housing having a distal end (D) and a proximal end (P) with an orifice intended to be applied against
an injection site, wherein the syringe is slidably arranged with respect to the housing,

a single drive spring configured when activated to
push the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal
end (P), and

to operate the syringe to supply the dose of medicament (M); and
a trigger assembly arranged to lock the drive spring in a compressed state prior to manual operation and capable of, upon
manual operation, releasing the drive spring for injection,

wherein the elongate tubular housing has a midpoint and comprises two tubular portions connected by a hinge positioned adjacent
the midpoint, the tubular portions rotatable about the hinge relative to each other between an aligned position and a maximum
opening angle, wherein the drive spring is compressed by rotating the tubular portions out of the aligned position towards
the maximum opening angle, wherein the trigger assembly locks the drive spring in the compressed state when the tubular portions
are rotated at least almost to the maximum opening angle and wherein a loading bay for holding the syringe is arranged in
one of the tubular portions, the loading bay being accessible from its distal end for loading or unloading the syringe when
the tubular portions are rotated out of the aligned position, wherein a lever is position outside of the elongate tubular
housing and is attached with one end to a fixed first pivot on an outside surface of one tubular portion, wherein the other
end of the lever is attached to a second pivot arranged at a sliding shuttle in the other tubular portion, the sliding shuttle
translatable in longitudinal direction of the other tubular portion between a maximum proximal position when the tubular portions
are aligned prior to activation of the trigger assembly and a maximum distal position when the tubular portions are rotated
at least almost by the maximum opening angle, wherein a drive collar arranged at a proximal end of the drive spring is engageable
by the sliding shuttle in order to compress the drive spring, characterized in that the one tubular portion is a proximal
portion and the other tubular portion is a distal portion, wherein the drive spring is a single drive spring used for providing
axial motion for advancing the syringe and injecting a dose of medicament (M).

US Pat. No. 9,320,854

DOSE SETTING MECHANISM WITH MAXIMUM DOSE LIMITED ELEMENT

Sanofi-Aventis Deutschlan...

1. A drug delivery device comprising a dose setting mechanism, the dose setting mechanism comprising
first maximum dose stop features on a first component part of said drug delivery device, wherein the first maximum dose stop
features comprise protrusions moulded onto an outer surface of the first component part,

corresponding second maximum dose stop features on a second component part of said drug delivery device,
with the first and second maximum dose stop features being designed to limit a relative rotational movement between said first
and second component parts,

a maximum dose limiting device comprising a maximum dose limiting sleeve,
the maximum dose limiting sleeve interposed on said first component part between said first and second maximum dose stop features
and

having mating features on a first end fitting to said first maximum dose stop features and
replica stop features on a second end replicating said first maximum dose stop features, wherein a thickness of the maximum
dose limiting sleeve is the same as a height of the protrusions moulded on to an outer surface of the first component part.

US Pat. No. 9,352,088

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament (M), comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), the housing having a distal end (D) and a proximal end (P) with an orifice intended to be applied against
an injection site, wherein the syringe is slidably arranged with respect to the housing,

spring means capable of, upon activation:
pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal
end (P),

operating the syringe to supply the dose of medicament (M), and
retracting the syringe with the needle into the covered position after delivering the medicament (M),
activating means arranged to lock the spring means in a pressurized state prior to manual operation and capable of, upon manual
operation, releasing the spring means for injection, wherein the spring means is a single drive spring in the shape of a compression
spring arranged to be grounded at a distal end in the housing for advancing the needle and for injecting the dose of medicament
(M) via a plunger and wherein the drive spring is arranged to have its ground in the housing switched to its proximal end
for retracting the syringe, wherein the activating means is arranged as a trigger button laterally arranged on the housing,

wherein an interlock sleeve is telescoped in the proximal (P) end of the housing, the interlock sleeve translatable in longitudinal
direction between a proximal position and a distal position and biased in proximal direction (P) in a manner to protrude from
the housing in the proximal position, wherein the interlock sleeve is arranged to be translated from its proximal position
into an intermediate position when pressed against the injection site, wherein the trigger button is arranged to push the
interlock sleeve from the intermediate position into the distal position thus releasing the drive spring.

US Pat. No. 9,186,467

NEEDLE ASSEMBLY COVER

Sanofi-Aventis Deutschlan...

1. A needle assembly system comprising:
a needle assembly including a needle and a needle support;
a cover including a distal portion adapted to house at least a distal end of the needle and a proximal portion adapted to
house the needle support,

wherein the proximal portion includes a first portion and a second portion, wherein the first portion has a first inner diameter
substantially equal to an outer diameter of the needle support such that the first portion of the proximal portion of the
cover is frictionally engaged with the needle support in a first position and the second portion has a second inner diameter
greater than the diameter of the needle support such that there is radial separation between the cover and the needle support
in a second position, wherein the second portion of the proximal portion has a length greater than or equal to a length of
the needle support, wherein the needle support is configured to be axially advanced from the first position to the second
position such that a proximal end of the needle assembly does not extend past a proximal end of the cover.

US Pat. No. 9,155,838

MEDICATED MODULE HAVING A DOUBLE NEEDLE GUARD

Sanofi-Aventis Deutschlan...

1. A medicated module attachable to a drug delivery device,
wherein the drug delivery device comprises a primary reservoir of a first medicament and wherein the medicated module comprises
a second medicament, the medicated module comprising:

a reservoir comprising the second medicament,
a housing having a proximal end and a distal end, where the housing is being configured for attachment to the drug delivery
device; wherein the reservoir of the medicated module is positioned within the housing by a first biasing member and a second
biasing member;

a first needle fixed in the housing,
a second needle fixed in a shuttle, wherein the shuttle is configured for axial movement relative to the housing,
first needle guard and a second needle guard adapted and arranged to provide protection against the second needle and operable
connected to move together axially in a proximal direction with respect to the housing during a first movement for a first
application to an injection site, wherein the first needle guard is configured to mechanically cooperate with the shuttle
for moving the shuttle with respect to the housing,

wherein a movement of the shuttle in the proximal direction opens fluid communication between the reservoir of the medicated
module and at least one of the first and the second needle.

US Pat. No. 9,352,092

MEDICATED MODULE WITH INTEGRAL FLOW DISTRIBUTION SYSTEM

SANOFI-AVENTIS DEUTSCHLAN...

1. A medicated module attachable to a drug delivery device, comprising;
a. a housing having a proximal end and a distal end, where the proximal end has a connector configured for attachment to a
drug delivery device;

b. a capsule comprising a vial that contains a medicament, where the capsule is encased within the housing and has top and
bottom seals;

c. a distally movable retention cap positioned in the proximal end of the housing;
d. a first needle fixed in the retention cap;
e. a second needle fixed within the distal end of the housing, wherein the top and bottom seals are configured for fluid engagement
with the first and second needles; and

f. a flow distribution system contained within the capsule, where the flow distribution system has two or more medicament
flow channels, wherein the vial comprises a cylindrical pin and wherein the two or more medicament flow channels are formed
between an inner surface of the vial and an outer surface of the pin.

US Pat. No. 9,289,560

DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive assembly for a drug delivery device, comprising:
a housing with a proximal end and a distal end, and a longitudinal axis (A) extending between the proximal end and the distal
end,

a rotation sleeve being rotatable relative to the housing,
a drive member is axially moveable relative to the housing, and
a piston rod being axially moveable relative to the housing,
wherein the piston rod is in mechanical cooperation with the rotation sleeve to be moveable in the distal direction relative
to the housing when the rotation sleeve rotates in a first direction (D1) and to be stationary in axial direction relative to the housing when the rotation sleeve rotates in a second direction (D2) opposite to the first direction (D1),

wherein the rotation sleeve is in mechanical cooperation with the drive member to be rotatable relative to the housing when
the drive member is displaced in axial direction relative to the rotation sleeve.

US Pat. No. 9,254,364

ASSEMBLY FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. An assembly for a drug delivery device, comprising:
a housing,
a dose member adapted to be rotated in a dose setting direction with respect to the housing for setting a dose of a drug and
to be rotated in a dose delivery direction with respect to the housing for delivering the set dose, the dose member comprising
a guide feature,

a guide track configured to mechanically cooperate with the guide feature, the guide track comprising a first section and
a second section which are connected to each other via a connection region, wherein the first section defines an angular start
position for the guide feature and the second section defines an axial stop position for the guide feature, and

a spring member,
wherein, when the dose member is rotated in the dose setting direction, the guide feature is angularly displaced from the
angular start position towards the connection region, the spring member is torsionally biased, the biased spring member tending
to angularly displace the guide feature towards the angular start position, and wherein, when the guide feature has passed
the connection region, the guide feature enters the second section and is axially displaced in a proximal direction with respect
to the housing towards the axial stop position, and, in the axial stop position, reduction of the torsional bias is prevented
by mechanical cooperation of the guide feature and the second section.

US Pat. No. 9,427,524

DRUG DELIVERY DEVICE WITH INTEGRATED EXTENDABLE/RETRACTABLE INFORMATION DISPLAY ELEMENT

Sanofi-Aventis Deutschlan...

1. An injection drug delivery device for dispensing of a dose of a medicinal product, comprising:
a housing having at least one housing component,
a holder for a cartridge, the cartridge comprising the medicinal product,
a dose dispensing mechanism operably engaged with the cartridge for setting and/or dispensing of a predefined dose of the
medicinal product, wherein the housing component serves as a housing for the dose dispensing mechanism, and

a spring biased display element movably disposed inside the at least one housing component,
an inner sleeve coupled to a helical spring and rotatably mounted in the housing component,
wherein the display element comprises a fixing element,
wherein the inner sleeve comprises a longitudinal slit adapted to receive the fixing element of the display element, and wherein
the fixing element is larger in size than the longitudinal slit,

wherein the display element is moveable for selectively concealing and/or revealing information provided on the display element
as the display element is moved into and out of the housing component,

wherein the display is rolled up on the inner sleeve, and wherein the inner sleeve is configured to surround at least a portion
of the dose dispensing mechanism.

US Pat. No. 9,220,447

APPARATUS FOR ELICITING A BLOOD SAMPLE

Sanofi-Aventis Deutschlan...

1. An apparatus for eliciting a blood sample comprising:
a housing having an aperture;
a shaft extending in the housing;
a testing member mounted on the shaft and configured to rotate with the shaft;
a lancing member pivotably mounted to the testing member, wherein the testing member has a recessed section in which the lancing
member is received and the recessed section defines a base extending along a plane parallel to but spaced apart from an uppermost
or a lowermost surface of the testing member, wherein a pivot axis of the lancing member is parallel to the longitudinal axis
of the shaft such that the lancing member is configured to pivot along a plane parallel to the plane of the base; and

a lancet protruding from the lancing member;
wherein the lancing member is configured to pivot relative to the testing member from a retracted position to a skin penetrating
position in which the lancet extends into or through the aperture when the testing member is rotated so that the lancing member
is coincident with the aperture.

US Pat. No. 9,375,174

ALLOWING MEASUREMENTS TO BE MADE OF A BLOOD SAMPLE

SANOFI-AVENTIS DEUTSCHLAN...

1. Apparatus for eliciting a blood sample, the apparatus comprising:
a housing having an aperture;
a shaft mounted inside the housing;
a testing member rotatably mounted on the shaft;
an actuating member coupled to the housing and configured to exert a force against the testing member; and
a lancet fixedly coupled to and protruding substantially radially from the testing member and configured to co-rotate with
the testing member;

wherein the apparatus is configured such that the lancet is aligned with the aperture in the housing when the testing member
is in a first position, and

wherein the testing member is configured, in the presence of a force exerted against the testing member by the actuator member,
to translate to a second position in which the lancet is in a skin penetrating position.

US Pat. No. 9,625,444

ARTIFICIAL IMMUNE SYSTEM: METHODS OF USE

SANOFI PASTEUR VAXDESIGN ...

1. A method for generating dendritic cells, comprising:
(a) culturing endothelial cells on an upper surface of a porous membrane, wherein said membrane is housed in an upper chamber
of a cell culture well that is suspended over, and is separable from, a lower chamber of the well;

(b) applying peripheral blood mononuclear cells (PBMCs) to the endothelial cells on the porous membrane of (a);
(c) removing the upper chamber housing the porous membrane and endothelial cells from the well about 48 hours after application
of the PBMCs; and

(d) isolating dendritic cells from the lower chamber of the well.

US Pat. No. 9,309,207

MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA

SANOFI, Paris (FR)

1. A compound of the formula (I)

or a stereoisomer thereof or a physiologically tolerated salt of any of the foregoing, wherein
X is —C(O)— or —SO2—;

U is an oxygen atom;
A is an oxygen atom, or —(C0-C4)-alkylene-;

V is
1) —(C5-C9)-alkylene-, wherein said alkylene is unsubstituted or substituted independently of one another once, twice or three times
by —OH, NH2 or halogen, or

2) —(C3-C9)-alkenylene-;

D is —(C1-C2)-alkylene-;

Y is
—(C6-C14)-aryl, wherein said aryl is unsubstituted or substituted independently of one another once, twice or three times by R15;

R1 is
1) a hydrogen atom,
2) —(C1-C6)-alkyl,

3) —(C1-C6)-alkyl-OH,

4) —(C0-C4)-alkyl-(C3-C6)-cycloalkyl,

5) —(C1-C10)-alkyl-O—C(O)—O—R2,

6) —(CH2)r—(C6-C14)-aryl, wherein said aryl is unsubstituted or substituted independently of one another once, twice or three times by R15,
and r is the integer zero, 1, 2 or 3, or

7) —(CH2)s-Het, wherein Het is a 4- to 15-membered heterocyclic ring system having 4 to 15 ring atoms which are present in one, two
or three ring systems which are connected together, and which comprise, depending on the ring size, one, two, three or four
identical or different heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, and in which Het is
unsubstituted or substituted independently of one another once, twice or three times by R15, and s is the integer zero, 1,
2 or 3;

R2 is
1) —(C1-C6)-alkyl,

2) —(CH2)r—(C6-C14)-aryl, wherein said aryl is unsubstituted or substituted independently of one another once, twice or three times by R15,
and r is the integer zero, 1, 2 or 3, or

3) —(C0-C4)-alkyl-(C3-C6)-cycloalkyl;

R3 is
1) —(C2-C6)-alkylene-NH2, wherein said alkylene is unsubstituted or substituted once, twice, three or four times by halogen,

2) —(C1-C4)-alkylene-O—(C1-C4)-alkylene-NH2,

3) —(C1-C4)-alkylene-SO2—(C1-C4)-alkylene-NH2,

4) —(C0-C4)-alkylene-Het, wherein said Het is as defined above and is substituted by —NH2 and once, twice or three times by R15,

5) —(C0-C4)-alkylene-(C3-C8)-cycloalkyl-NH2, or

6) —(C0-C6)-alkylene-cyclic amine, wherein the cyclic amine is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl,
piperazinyl, azepinyl, morpholinyl, and thiomorpholinyl;

R6 is
1) a hydrogen atom,
2) —(C1-C6)-alkyl, wherein said alkyl is unsubstituted or substituted independently of one another once, twice or three times by R16,

3) —O—(C1-C6)-alkyl, wherein said alkyl is unsubstituted or substituted independently of one another once, twice or three times by R16,

4) —(C0-C4)-alkylene-Het, wherein said Het is as defined above, wherein said alkylene and Het are unsubstituted or substituted independently
of one another once, twice or three times by R16,

5) —(C0-C4)-alkylene-aryl, wherein said alkylene and aryl are unsubstituted or substituted independently of one another once, twice
or three times by R16, or

6) —(C0-C4)-alkylene-(C3-C8)-cycloalkyl, wherein said alkylene and cycloalkyl are unsubstituted or substituted independently of one another once, twice
or three times by R16;

R7 is a hydrogen atom, halogen or —(C1-C6)-alkyl;

R8 is a hydrogen atom, halogen or —(C1-C6)-alkyl;

R9 is a hydrogen atom, halogen or —(C1-C6)-alkyl;

R15 is a hydrogen atom, —(C1-C4)-alkyl, —O—CF3, —NH2, —OH, —CF3 or halogen; and

R16 is —O—CF3, —NH2, —OH, —CF3 or halogen.

US Pat. No. 9,061,103

AUTO-INJECTOR

SANOFI-AVENTIS DEUTSCHLAN...

1. An auto-injector for delivering a liquid medicament, the auto-injector comprising an elongate housing having a longitudinal
axis and a loading bay configured to receive a packaged syringe, wherein the loading bay is configured to be laterally accessible
for inserting or removing the packaged syringe, wherein a sliding door is slidably arranged over the housing in a manner to
reveal the loading bay when the sliding door is moved axially along the longitudinal axis to a distal position and to cover
the loading bay when the sliding door is moved axially along the longitudinally axis to a proximal position, and where moving
the door in a proximal direction causes compression of a drive spring,
wherein the packaged syringe comprises a syringe with a hollow injection needle and a stopper for sealing the syringe and
displacing the liquid medicament,

wherein the drive spring is arranged in the housing for advancing the syringe and the needle in a proximal direction for needle
insertion into an injection site and for injecting the medicament through the needle,

wherein the sliding door exhibits a door rack gear in mesh with a drive gear which is in mesh with a drive reset rack such
that the sliding door and the drive reset rack translate in opposite directions, and

wherein the drive reset rack is arranged to compress the drive spring on translation in a distal direction.
US Pat. No. 9,056,833

CRYSTALLINE PHASES OF 2?-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE

SANOFI-AVENTIS DEUTSCHLAN...

1. A form of 2?-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid(2-pyridin-3-yl-ethyl)-amide comprising
polymorph 1 thereof.

US Pat. No. 9,486,587

ASSEMBLY FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. An assembly for a drug delivery device, comprising:
a housing having a proximal end and a distal end;
a dose member which is displaceable in the proximal direction with respect to the housing for setting of a dose of a drug;
a clutch member which is displaced in the proximal direction with respect to the housing when setting the dose; and
a stop member configured to define a clutch stop position for the proximal displacement of the clutch member with respect
to the housing, with the clutch member, when in the clutch stop position, being prevented from further displacement in the
proximal direction with respect to the housing,

wherein the clutch member and the dose member are configured to mechanically cooperate with one another when the clutch member
is in the clutch stop position, thereby preventing further displacement of the dose member in the proximal direction with
respect to the housing during setting of the dose,

wherein the dose member is threadedly connected to the housing,
wherein the dose member is rotated in a first direction with respect to the housing and displaced in the proximal direction
with respect to the housing for setting of the dose, and

wherein the clutch member does not rotate with respect to the housing during setting of the dose.

US Pat. No. 9,463,286

MEDICAMENT RESERVOIR FOR A MEDICATED MODULE

SANOFI-AVENTIS DEUTSCHLAN...

1. A reservoir assembly for a medicated module, the reservoir assembly comprising:
a primary cavity for holding a medicament wherein the primary cavity has a proximal end, a distal end, and is located along
a central axis of the medicated module; a sump region, wherein the sump region comprises one or more cavities arranged around
the primary cavity;

a flexible element, wherein the flexible element is configured to allow for fluid communication between the primary cavity
and the sump region during a pressure filling process for the reservoir assembly, and wherein the flexible element is configured
to prevent fluid communication between the primary cavity and the sump region after the filling process, when the pressure
is removed;

a proximal primary-cavity bung configured to seal the proximal end of the primary cavity; and
a distal primary-cavity bung configured to seal the distal end of the primary cavity.

US Pat. No. 9,358,345

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament, the auto-injector having a distal end and a proximal
end with an orifice intended to be applied against an injection site and comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament, wherein the syringe is slidably arranged with respect to the housing,

a drive capable of, upon activation:
pushing the needle from a retracted position into an advanced position through the orifice and past the proximal end, and
operating the syringe to supply the dose of medicament,
a plunger for transmitting power from the drive to at least one of the syringe and the stopper,
a plunger arm attached to the plunger and comprising a dog, and
a shuttering mechanism arranged to lock the drive in a compressed state prior to manual operation and capable of, upon manual
operation, releasing the drive for injection, the shuttering mechanism further being arranged to control translation of the
plunger and comprising:

a fixed shutter attached to the housing and comprising a fixed protrusion, the fixed protrusion arranged to engage the dog
of the plunger arm to prevent translation of the plunger in a proximal direction, the dog of the plunger arm being resiliently
biased toward the fixed shutter, and

a moving shutter arm arranged alongside the fixed shutter and moveable between a locking position and an unlocking position,
the moving shutter arm comprising a moving protrusion with a ramp, the moving shutter arm being configured to:

disengage the dog from the fixed protrusion when the moving shutter arm is moved to the locking position and the dog is engaged
to the fixed protrusion, and

enable the dog to engage with the fixed protrusion when the moving shutter arm is in the unlocking position.

US Pat. No. 9,205,199

AUTO-INJECTOR WITH NEEDLE SHROUD AND NEEDLE PROTECTION CAP

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament (M), the auto-injector having a distal end (D) and a proximal
end P with an orifice intended to be applied against an injection site and comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), wherein the syringe is slidably arranged with respect to the housing,

a driver capable of, upon activation:
pushing the needle from a covered position into an advanced position through the orifice and past the proximal end (P), and
operating the syringe to supply the dose of medicament (M), and
a trigger mechanism arranged to lock the driver in a compressed state prior to manual operation and capable of, upon manual
operation, releasing the driver for injection,

characterized in that a shroud is arranged at least partially inside the housing, the shroud slidable in longitudinal direction
between at least a retracted position, in which the needle is exposable and an advanced position, in which the needle is covered
by the shroud, wherein the shroud is arranged to be locked in the retracted position prior to manual operation of the trigger
mechanism and wherein the shroud is arranged to be pushed towards the advanced position by a syringe spring when the driver
has been released, wherein a protective needle shield is attachable to the needle in a manner to partially protrude beyond
the proximal end of the shroud through the orifice with the needle in its advanced position, wherein a syringe carrier is
arranged inside the shroud for holding the syringe, the syringe carrier slidable with respect to the shroud, wherein the syringe
carrier comprises at least one resilient snap for locking it to the shroud in order to prevent relative axial motion, wherein
the snap is arranged to be supportable from inside by the protective needle shield when attached to the needle in order to
remain engaged with the shroud and wherein the snap is inwardly biased to disengage from the shroud without support from inside
in a manner to automatically disengage upon removal of the protective needle shield, thus allowing the syringe and needle
to be retracted into the covered position under load of the syringe spring.

US Pat. No. 9,427,533

MEDICATED MODULE FOR AN INHALER

SANOFI-AVENTIS DEUTSCHLAN...

1. A medicated module configured for use with a drug inhaler containing a first medicament, the medicated module comprising:
a housing configured for attachment to the drug inhaler, where the housing has a distal end with a first opening and a proximal
end with a second opening and a flow path extending between the first opening and the second opening;

a medicament container containing a dose of a second medicament; a seal attached to the housing to prevent the second medicament
from entering the flow path;

a de-aggregation chamber configured to accept the second medicament from the medicament container upon opening the seal of
the medicament container; and

a sliding member connected to the medicament container;
wherein the medicated module is configured such that attachment to the drug inhaler causes the sliding member to move in a
distal direction such that the medicament container moves from a first position to a second position,

wherein the second position is closer to the second opening than the first position, and
wherein the movement of the container from the first position to the second position causes the seal to break, thereby opening
the medicament container to the flow path, such that the first opening and the second opening are in fluid communication with
the first medicament and the second medicament.

US Pat. No. 9,402,959

ASSEMBLY FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. An assembly for a drug delivery device comprising
a housing body having a longitudinal axis;
a drive assembly having a drive member, the drive member being configured to be axially displaced with respect to the housing
body during operation of the drive assembly for at least one of (i) setting a dose of a drug or (ii) dispensing the dose of
the drug; and

a display assembly having a display and an indicator element, the indicator element being axially displaceable with respect
to the housing body along the longitudinal axis;

wherein
the display is configured such that it displays a first state through a window where the indicator element is only visible
through the window when the indicator element is in a first position, and where the display switches to a second state when
the indicator element is displaced away from the first position and is no longer visible through the window and only the drive
member or another element of the drive assembly is visible through the window, and

the drive assembly is configured such that the drive member transfers a force to the indicator element which force displaces
the indicator element away from the first position when the drive assembly carries out a priming step, where a switch from
the first state to the second state occurs during the priming step when a first portion of the drug is dispensed for a first
time,

wherein the drive member is operable to hold the indicator element in a resiliently biased position when the drive member
is in a rest position;

wherein the drive member is inoperable to transfer said force to the indicator element when the indicator element is in the
resiliently biased first position, and wherein the drive member is operable to transfer said force to the indicator element
when the indicator element is in an interaction position; and

wherein the assembly is configured such that the indicator element can move radially from the resiliently biased position
to the interaction position when the drive member is displaced by a predetermined distance from the rest position in a first
axial direction.

US Pat. No. 9,238,110

MEDICATED MODULE HAVING A COLLAPSIBLE FEATURE

Sanofi-Aventis Deutschlan...

1. A medicated module attachable to a drug delivery device, the drug delivery device having a drug reservoir holding a first
medicament, the medicated module comprising:
an upper retention feature;
a lower retention feature, wherein the upper retention feature is axially moveable relative to the lower retention feature;
attachment means provided at the lower retention feature for attachment of the module to the drug delivery device;
an upper engagement needle;
a lower output needle, wherein the output needle is in fluid communication with the engagement needle, wherein at least one
of the output needle and the engagement needle is fixed to the lower retention feature; and

a reservoir holding a second medicament, wherein the reservoir is operably connected to the upper retention feature and located
upwardly from said engagement needle,

wherein when the medicated module is attached to the drug delivery device,
(i) at a first predetermined amount of axial displacement between the upper and lower retention feature, the upper retention
feature is configured to move relatively towards the lower retention feature and the engagement needle such that fluid communication
between the engagement needle and the reservoir is established, and

(ii) at a second predetermined amount of axial displacement between the upper and lower retention feature, a protrusion provided
by the lower retention feature contacts and compresses the reservoir,

(iii) such that at least one of the engagement needle and the output needle is primed with the second medicament, and wherein,
during dispense and after priming, substantially all the second medicament is dispensed before the first medicament is dispensed.

US Pat. No. 9,345,832

CARTRIDGE HOLDER AND DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A cartridge holder for a drug delivery device, which houses a cartridge having a hermetically sealed distal end section,
comprising:
a proximal portion for receiving the cartridge filled with a medicinal fluid to be dispensed by the drug delivery device,
a distal portion comprising a mount for a piercing assembly, wherein the piercing assembly is adapted to provide a fluid-transferring
connection with an inner volume of the cartridge by way of a piercing element pointing in a distal direction with a pointed
free end section, and wherein the piercing assembly comprises a planar shaped bottom portion;

wherein the distal portion is opened towards its distal end, such that the piercing assembly provides a distal end stop for
the cartridge across the entire inner surface of its bottom portion when assembled with the cartridge holder,

wherein the distal portion is void or is free of a radially inwardly directed flange portion at its distal end section;
wherein a distal end face of the cartridge is substantially surface-flushed with a distal end of the cartridge holder, and
a distal end of the cartridge almost entirely abuts against the inside of the bottom portion of the piercing assembly in order
to prevent post-dispensing droplet generation;

wherein the distal portion further comprises an outside thread adapted to threadedly receive a corresponding inner thread
of the piercing assembly and

retaining means adapted to substantially prevent the cartridge from displacing in a proximal direction with respect to the
proximal portion and/or distal portion characterized in that:

the distal portion is integrally formed with the proximal portion being larger in inner diameter than the distal portion,
and

wherein the retaining means comprise axially and/or circumferentially extending retaining ribs arranged along an inside wall
of the distal portion adapted to retain the cartridge in a press-fit.

US Pat. No. 9,228,203

RECOMBINANT BICISTRONIC FLAVIVIRUS VECTORS

Sanofi Pasteur Biologics,...

1. A method of administering a protein or peptide to a subject, the method comprising administering to the subject a chimeric
flavivirus comprising structural sequences of a first flavivirus and non-structural sequences of a yellow fever virus, wherein
the genome of said chimeric flavivirus comprises an internal ribosome entry site and a transgene located in the 3?-untranslated
region of the flavivirus.
US Pat. No. 9,173,955

MULTIVALENT MENINGOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE

Sanofi Pasteur Inc., Swi...

1. A method of vaccinating a human susceptible to infection due to Neisseria meningitidis comprising administering to the human an immunologically effective amount of an immunological composition comprising a mixture
of four distinct and separately made protein-capsular polysaccharide conjugates, wherein the first conjugate comprises purified
Neisseria meningitidis capsular polysaccharide of serogroup W-135 conjugated to a purified carrier protein, the second conjugate comprises purified
N. meningitidis capsular polysaccharide of serogroup Y conjugated to a purified carrier protein, the third conjugate comprises purified N. meningitidis capsular polysaccharide of serogroup A conjugated to a purified carrier protein, and the fourth conjugate comprises purified
N. meningitidis capsular polysaccharide of serogroup C conjugated to a purified carrier protein, wherein the immunological composition has
the capacity to elicit in children less than two years of age a primary serum IgG response and a serum bactericidal antibody
response to each of the N. meningitidis serogroups A, C, W-135 and Y capsular polysaccharides, wherein said serum bactericidal antibody response is higher than that
elicited by the licensed, unconjugated, tetravalent A, C, W-135 and Y meningococcal capsular polysaccharide vaccine, and further
wherein the immunological composition has the capacity to elicit a booster anamnestic IgG response to each of the N. meningitidis serogroups A, C, W-135and Y capsular polysaccharides.

US Pat. No. 9,132,242

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament, comprising:
an elongate outer casing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament, the outer casing having a distal end and a proximal end with an orifice intended to be applied against an
injection site, wherein the syringe is slidably arranged with respect to the outer casing,

spring means capable of, upon activation:
pushing the needle from a covered position inside the outer casing into an advanced position through the orifice and past
the proximal end,

operating the syringe to supply the dose of medicament, and
retracting the syringe with the needle into the covered position after delivering the medicament,
activating means arranged to lock the spring means in a pressurized state prior to manual operation and capable of, upon manual
operation, releasing the spring means for injection,

wherein the spring means is a torsion spring grounded at one end in the outer casing and at the other end in a first gear
member rotatable about a longitudinal axis, wherein the first gear member, upon rotation, is arranged for translatively moving
a second gear member toward the proximal end, the second gear member prevented from rotating and arranged to be coupled to
the stopper in order to push it towards the proximal end, wherein the first gear member is engaged with the activating means
prior to manual operation in a manner to prevent rotation and disengaged from the activating means upon manual operation,

characterized in that at least one skin contact trigger element is arranged at the proximal end of the outer case, the skin
contact trigger element translatable in longitudinal direction between a proximal position and a distal position and biased
in proximal direction in a manner to protrude from the outer casing in the proximal position, wherein in its proximal position
the skin contact trigger element is arranged to prevent the spring means from being released and wherein the skin contact
trigger element in its distal position is arranged to allow release of the spring means.

US Pat. No. 9,233,211

RELATING TO A PEN-TYPE INJECTOR

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism for use in a drug delivery device comprising:
a housing comprising an inner surface and an insert that is rotationally and axially fixed relative to the housing;
a drive sleeve having an outer surface, where a first end of the drive sleeve comprises a first radially extending flange
and a second radially extending flange, where threads are disposed on the outer surface between the flanges and the first
flange is configured to conform to a second side of the insert; and

a nut threadedly engaged with the threads on the outer surface of drive sleeve between the two radially extending flanges,
where the nut has an outer surface keyed to the inner surface of the housing to prevent relative rotation between the nut
and the housing while allowing relative longitudinal movement between the nut and the housing and where the nut translates
distally relative to the drive sleeve during dose setting and is axially fixed relative to the drive sleeve during dose delivery.

US Pat. No. 9,234,025

EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR

SANOFI, Paris (FR) VIB V...

1. A method for identifying an allosteric inhibitor of a receptor tyrosine kinase (RTK) comprising the steps of:
a) contacting an allosteric binding site of a RTK with a small compound allosteric inhibitor candidate compound;
b) measuring the state of at least one reporter for the ERK1/2 signalling pathway and the state of at least one reporter for
the PLC? signalling pathway before and after the contacting step (a);

c) comparing any changes in the state of the at least one reporter for each of the ERK1/2 signalling pathway and the PLC?
signaling pathway induced by the contacting step (a); and

d) identifying an allosteric inhibitor of the RTK when, in the presence of the small compound allosteric inhibitor candidate
compound bound to the allosteric binding site of the RTK, one of the ERK1/2 or PLC? signalling pathway is inhibited and the
other pathway is unaffected.

US Pat. No. 9,226,956

IMMUNIZATION AGAINST CLOSTRIDIUM DIFFICILE DISEASE

Sanofi Pasteur Biologics,...

1. A method for eliciting an immune response to Clostridium difficile in a human in need of such an immune response, the method comprising administering to the human a composition comprising a
toxoid of Clostridium difficile toxin A and a toxoid of Clostridium difficile toxin B, wherein the proportion of the toxoid of Clostridium difficile toxin A present in the composition is greater than that of the toxoid of Clostridium difficile toxin B.

US Pat. No. 9,486,586

DRUG DELIVERY DEVICE AND METHOD FOR DETECTING A CONTACT

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device comprising:
a cartridge with a movable bung,
a drive mechanism including a piston rod configured as a lead screw with a bearing at a distal end for driving the bung in
a distal direction, and

a movable element, which is disposed displaceably in an axial direction within the drive mechanism,
wherein the moveable element is movable between a first position in which a distal end of said movable element protrudes from
said bearing and a second position in which a distal end of said movable element lies flush with the distal end of said bearing,

wherein the movable element is disposed in a center hole extending through the bearing in axial direction.

US Pat. No. 9,375,169

CAM DRIVE FOR MANAGING DISPOSABLE PENETRATING MEMBER ACTIONS WITH A SINGLE MOTOR AND MOTOR AND CONTROL SYSTEM

SANOFI-AVENTIS DEUTSCHLAN...

1. An analyte and detecting apparatus, comprising:
a housing;
a disposable positionable in the housing;
a penetrating member driver positioned in the housing;
a plurality of penetrating members positioned in the disposable and each of a penetrating member being configured to be coupled
to the penetrating member driver;

a plurality of sampling chambers each including an analyte sensor, each sampling chamber associated with a penetrating member;
a cam disk indexing and drive mechanism, wherein the cam disk indexing and drive mechanism being configured to move in x-y
and y-z directions that provide for movement in three orthogonal directions;

at least one seal that covers the penetrating members;
a punching element that punches the seal prior to a launch of a penetrating member;
a gripper that couples the penetrating member driver with a penetrating member, the cam disk indexing and drive mechanism
configured to retain and release the gripper; and

a motor and control system that provides cam disk indexing and drive mechanism movements including, punching the at least
one seal and coupling the gripper to a penetrating member.

US Pat. No. 9,599,589

METHOD FOR SENSING ARRIVAL AND MONITORING FLOW OF A SAMPLE IN A TESTING DEVICE

Sanofi-Aventis Deutschlan...

1. A method for sensing arrival and monitoring flow of a sample in a testing device, comprising:
providing a meter relay for sensing a sample arrival in the testing device that includes three electrodes for measurement
of an analyte in a sample that includes a switch located in an analog or digital part of a circuit, the testing device including
a reference electrode lead, a counter electrode lead, and a working electrode, the metal including a cartridge positionable
in the testing device and a disc,

in a start condition having a counter relay open;
using first and second electrodes in an auto-trigger function;
starting a measurement when the sample wets the second electrode until a current reaches a threshold level of from 50 to 2,000
Na;

closing counter relays for the testing device when a threshold level is reached; and
providing a dual rotation and indexing of the disc and the cartridge.

US Pat. No. 9,494,264

CODED DRUG RESERVOIR CONNECTION ELEMENT WITH HINGE

Sanofi-Aventis Deutschlan...

1. A cartridge adaptor comprising:
a main body having a proximal end, a distal end, and a bore configured to receive a cartridge containing a medicament and
having a bead at the distal end, the main body further comprising a first segment attached to a second segment by a hinge
that extends along at least a portion of a length of the main body from the proximal end to the distal end or along a chord
on the distal top of the main body, and a retention feature on the main body comprising a protrusion located within the bore
and suitable for snapping under the bead of the cartridge for securing the cartridge adaptor to the cartridge;

wherein an outer surface of the first segment comprises a first outer threaded portion and an outer surface of the second
segment comprises a second outer threaded portion.

US Pat. No. 9,463,279

MEDICAL DEVICE AND METHOD OF ASSEMBLY

Sanofi-Aventis Deutschlan...

1. A drug delivery device for administering a liquid drug to a patient comprising:
a cartridge filled with the liquid drug and having a piston slidably disposed therein,
a main housing component and
a drive mechanism, wherein the drive mechanism is accommodated inside the main housing component,
wherein the drive mechanism is operably engageable with the piston of the cartridge to expel a dose of the liquid drug from
the cartridge and wherein the drive mechanism comprises a piston rod with a pressure piece at a distal end section to but
against a proximal end face of the piston of the cartridge;

wherein at least the pressure piece located inside the main housing component comprises a thermoplastic material having an
additive embedded and homogeneously distributed in its bulk,

wherein the additive is adapted to provide a visually perceptible signal when exposed to electromagnetic radiation and
wherein the electromagnetic radiation is within one of a first spectral range, a second spectral range, or a third spectral
range.

US Pat. No. 9,440,031

DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device comprising:
a housing having a distal end comprising a needle holder having an outer surface with an outer diameter, where the outer surface
is configured with a connector that engages a needle unit such that the needle unit is attached to the outer surface of the
housing, where the needle unit has an outside diameter greater than the outer diameter of the needle holder and

a reusable cap having an inner surface and configured to cover the distal end of the housing and comprising a retaining member
configured to engage and re-engage a corresponding mating member located proximate to the needle holder on the housing to
secure the cap to the housing repeatedly when the needle unit is not attached to the housing, where the cap has a protruding
element on the inner surface that extends radially inward a distance such that it contacts the needle unit when a user attempts
to the replace the cap on the distal end of the housing to prevent the retaining member from engaging the corresponding mating
member when the needle unit is attached to the needle holder thereby providing feedback to a user to remove the needle unit
before the cap can be replaced on the housing, wherein the at least one protruding element is formed as either (i) a step
along the inner side wall of the cap or (ii) at least one rib on the inner side wall of the cap, the at least one rib being
arranged along a longitudinal axis being arranged between the distal end and the proximal end.

US Pat. No. 9,370,624

ASSEMBLY FOR USE IN A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A piston and plunger combination for use in a drug delivery device comprising,
a) a piston having a body comprising a distal end face and a proximal thrust receiving surface, wherein the piston further
comprises a radial sealing surface that is configured to engage an inner sidewall of a cartridge to provide a leak proof seal;

b) a plurality of centering elements protruding proximally from the proximal thrust receiving surface,
c) a plunger having a distal facing end face; and
d) a receptacle on the distal facing end face having a geometric shape and depth, where the geometric shape of the receptacle
is a substantially U- or V-shaped groove of circular geometry as viewed in a plane parallel to the distal facing end face,

wherein the plurality of centering elements are arranged on the proximal thrust receiving surface in a pattern that matches
the geometric shape of the receptacle and protrude outwardly from the proximal thrust receiving surface a distance less than
or equal to the depth of the receptacle such that the distal facing end face is in contact with the proximal thrust receiving
surface when the plunger and piston abut,

wherein each of the plurality of centering elements when as viewed in a plane parallel to the proximal thrust receiving surface
comprise an arcuate shape.

US Pat. No. 9,492,622

NEEDLE SAFETY ARRANGEMENT AND METHOD FOR OPERATING IT

Sanofi-Aventis Deutschlan...

1. A needle safety arrangement for protecting a hollow injection needle of a syringe after an injection, the needle safety
arrangement comprising:
a needle sheath having essentially the shape of a hollow cylinder arranged to surround the needle, the needle sheath slidable
in longitudinal direction with respect to the syringe and biased in proximal direction (P),

a sheath linkage, slidable in longitudinal direction,
a syringe carrier for holding the syringe, the syringe and syringe carrier arranged for joint axial translation and rotation
relative to the needle sheath,

wherein the sheath linkage is configured to restrict translation in proximal direction (P) with respect to the syringe by
abutting against the syringe carrier, wherein in an initial state the sheath linkage is abutted against the syringe carrier
and latched to the needle sheath for joint axial translation, wherein the syringe carrier exhibits at least one cam on its
circumference, wherein the cam is arranged to de-latch the needle sheath from the sheath linkage on rotation of the syringe
carrier so as to release the needle sheath for being translated in proximal direction (P) and cover the needle, wherein the
syringe carrier is arranged to be rotated by at least one ramp on translation from an initial distal position in proximal
direction (P) so as to de-latch the needle sheath from the sheath linkage.

US Pat. No. 9,345,834

AUTOINJECTOR

Sanofi-Aventis Deutschlan...

1. An autoinjector comprising:
a case;
a drive carriage disposed in the case;
a plunger coupled to the drive carriage, the plunger adapted to releasably engage a needle retraction mechanism in a syringe,
wherein the plunger includes proximal resilient arms;

a latch tube coupled to the plunger, the latch tube including resilient arms and a proximal aperture;
wherein when the drive carriage abuts the latch tube, the proximal resilient arms of the plunger are deflected by the proximal
aperture in the latch tube and the plunger translates in a proximal direction relative to the drive carriage under a force
of a plunger spring,

wherein when an interlock sleeve translates in a distal direction relative to the case, hooks on the interlock sleeve disengage
the resilient arms on the latch tube, the resilient arms deflect and the drive carriage engages the latch tube,

wherein translation of the drive carriage in the distal direction relative to the case causes the plunger to engage the needle
retraction mechanism.

US Pat. No. 9,347,707

ROTARY DRUM FOR USE IN A VACUUM FREEZE-DRYER

Sanofi Pasteur SA, Lyons...

1. A rotary drum for use within a vacuum chamber in a vacuum freeze-dryer for the bulkware production of freeze-dried particles,
the rotary drum being rotatable, wherein the rotary drum is adapted for unloading the freeze-dried particles after the drying
process is finished, and wherein
the rotary drum is in open communication with the vacuum chamber and comprises a main section terminated by a front plate
and a rear plate;

the rear plate is adapted for connection with a rotary supporting shaft for rotary support of the rotary drum, and
the rear plate is permeable for sublimation vapor from freeze-drying the particles.

US Pat. No. 9,295,785

FRONT END FOR AN AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. A front end for an auto-injector, the front end comprising: a syringe with an injection needle and a stopper, wherein the
syringe is slidably arranged within a syringe retainer, wherein an outer sleeve for preventing access to the needle is removably
arrangeable over the syringe retainer, wherein the syringe retainer comprises a screw thread for connecting it to a correspondent
screw thread of a mounting of a re-usable auto-injector back end comprising a drive means for advancing the syringe and needle
in a proximal direction for needle insertion and for advancing the stopper within the syringe for injection, wherein a resilient
locking barb is arranged on the syringe retainer proximally from the screw thread of the syringe retainer, wherein the resilient
locking barb is arranged to rotationally lock the syringe retainer to the mounting in an unscrewing direction when the front
end is screwed to the re-usable back end and when the outer sleeve is removed, and the resilient locking barb exhibits a chamfer
for inwardly deflecting the resilient locking barb by an internal surface of the mounting when rotated in a screwing direction,
wherein the outer sleeve is arranged to unlock the resilient locking barb when arranged over the syringe retainer, the resilient
locking barb being arranged to partially remain outside of the mounting so as to allow the outer sleeve to inwardly deflect
the locking barb to unlock it, and wherein the resilient locking barb is arranged to engage an internal groove arranged in
the mounting.
US Pat. No. 9,295,721

PROCESS FOR STABILIZING AN ADJUVANT CONTAINING VACCINE COMPOSITION

Sanofi Pasteur SA, Lyons...

1. A stabilized dry Haemophilus influenzae vaccine composition comprising micropellets or particles, wherein the micropellets or particles are grilled micropellets or
particles with a diameter from about 200 ?m to about 1500 ?m, wherein the micropellets or particles are obtained by a process
comprising,
a) diluting a liquid bulk antigen composition comprising a conjugated or non-conjugated polysaccharide antigen or an antigenic
preparation from Haemophilus influenzae with an aqueous solution comprising a carbohydrate, a sugar alcohol, or a mixture thereof in order to obtain a diluted vaccine
composition solution wherein the concentration of the carbohydrate, sugar alcohol, or mixture thereof is from 2% (w/v) to
the limit of solubility,

b) prilling the diluted vaccine composition solution to form calibrated droplets of the vaccine having a diameter of approximately
from about 200 ?m to about 1500 ?m,

c) subjecting the droplets of the vaccine to freezing to form frozen spherical micropellets or particles of the vaccine, and
d) drying the frozen spherical micropellets or particles of the vaccine to form dry spherical micro-pellets or particles of
the vaccine having a diameter from about 200 ?m to about 1500 ?m.

US Pat. No. 9,233,214

INJECTION DEVICE

Sanofi-Aventis Deutschlan...

1. An injection device, comprising a syringe with a hollow needle and a stopper for sealing the syringe and displacing a medicament
(M) stored in the syringe, the injection device further comprising a drive means, a plunger arranged for pushing against the
stopper and an arrangement for transferring a translation of the drive means to the plunger, wherein the arrangement comprises
an elongate release latch member pivoted at one end which is connected to either the drive means or the plunger, the release
latch member having another end for engaging the respective other one of the drive means or the plunger, wherein the release
latch member is arranged to have its non-pivoted other end disengaged by rotation due to contact between at least one ramp
and another component when the stopper has at least nearly displaced all of a predefined dose of the medicament (M), wherein
a length of the release latch member is specified so as to provide a clearance between the plunger and the drive means when
the release latch member is engaged in order to allow at least the plunger, the stopper and the hollow needle to be retracted
at least far enough to hide the needle inside the syringe or inside a housing after disengaging the release latch member,
wherein the release latch member is arranged to be disengaged depending on a distance travelled until at least all of the
predefined dose has been delivered,

wherein the release latch member is arranged to be disengaged depending on a time elapsed from a beginning of the translation,
wherein a damper unit is arranged in series with the drive means and the release latch member, the damper unit comprising
a viscous damper, and

wherein the viscous damper comprises a piston fixed to a drive collar by a connecting rod, the drive collar being arranged
at a proximal end of the drive means, the piston having a greater diameter than the connecting rod, wherein a hollow cylinder
with an internal diameter slightly greater than the diameter of the piston is arranged around the piston thus allowing the
piston and cylinder to reciprocate, wherein a proximal end face of the cylinder is fully closed and wherein a distal end face
of the cylinder is arranged to seal the cylinder against the connecting rod, wherein at least one transfer port is provided
through the piston in a manner to allow a fluid to flow between the distal side of the piston and the proximal side.

US Pat. No. 9,574,004

METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST

Sanofi Biotechnology, Pa...

1. A method for the treatment of persistent asthma that reduces the incidence of asthma exacerbations or improves one or more
asthma-associated parameter(s) in a subject with persistent asthma comprising sequentially administering to the subject a
single initial dose of a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof, wherein
the antibody or antigen-binding fragment thereof specifically binds an interleukin-4 receptor (IL-4R), and wherein administration
of the single initial dose is followed by one or more secondary doses of the pharmaceutical composition comprising the antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises heavy chain and light
chain complementarity determining region (CDR) sequences from a heavy chain variable region (HCVR)/light chain variable region
(LCVR) sequence pair of SEQ ID NOs: 162/164.

US Pat. No. 9,572,525

ALLOWING MEASUREMENTS TO BE MADE OF A BLOOD SAMPLE

Sanofi-Aventis Deutschlan...

1. Apparatus for allowing measurements to be made of a blood sample, the apparatus comprising:
a shaft;
at least first and second blood collection members engaged to the shaft, wherein the at least first and second blood collection
members are independently rotatable about the shaft, each of the at least first and second blood collection members including:

a blood analysis part for receiving a blood sample,
plural conductive contacts, and
plural conductors extending between the blood analysis part and respective ones of the conductive contacts; and
plural terminals configured to provide an electrical connection with the plural conductive contacts on the first blood collection
member when the apparatus is in a first configuration and to provide an electrical connection with the plural conductive contacts
on the second blood collection member when the apparatus is in a second configuration, thereby allowing successive measurements
of at least one parameter of blood samples provided on the blood analysis parts of the at least first and second blood collection
members,

wherein the plural terminals are supported on a terminal carrier that is configured to be moveable such that the plural terminals
can move to contact the conductive contacts of one of the at least first and second blood collection members when the one
of the at least first and second blood collection members is at least at a predetermined rotation, and

wherein the terminal carrier is configured to be moveable in a direction that is substantially perpendicular to the longitudinal
axis of the shaft at a location where the plural terminals contact the plural conductive contacts.

US Pat. No. 9,452,262

DRUG DELIVERY DEVICE AND ASSOCIATED PACKAGING

Sanofi-Aventis Deutschlan...

1. A drug delivery device for dispensing of a user settable dose of a medicinal product, comprising:
a housing, and
a drive mechanism comprising an axially displaceable piston rod to act on a piston of a cartridge containing the medicinal
product to be dispensed,

wherein the drug delivery device is further provided with a protective cover attached across a dose indicating unit of the
drug delivery device, the dose indicating unit indicating the size of a user settable dose,

wherein the protective cover is adapted to irreversibly increase a degree of opacity and to decrease a degree of transparency
in response to an ambient temperature rising above or dropping below at least one predefined threshold,

wherein the protective cover is substantially transparent prior to the ambient temperature crossing the at least one threshold,
so that the user settable dose is viewable, and

wherein the protective cover becomes and remains substantially non-transparent in response to a crossing of the ambient temperature
above or below the at least one predefined threshold, so that the user settable dose is no longer viewable.

US Pat. No. 9,365,832

PURIFICATION OF HERPES VIRUS

SANOFI PASTEUR BIOLOGICS,...

1. A method for the purification of herpes simplex virus (HSV) particles from a mammalian host cell culture comprising the
steps of:
a) treating the mammalian host cell culture with a viral releasing agent to release the HSV particles from the host cells;
b) treating the material from step (a) with an endonuclease;
c) filtering the material from step (b) to remove any intact cells or cellular debris;
d) applying the solution obtained from step (c) to an anion exchange chromatography resin;
e) eluting the HSV particles from the anion exchange column;
f) subjecting the eluent from step (e) to tangential flow filtration; and
g) recovering the purified HSV particles.

US Pat. No. 9,297,370

MEDICAL INJECTION DEVICE WITH ELECTRIC MOTOR DRIVE CONTROL

Sanofi-Aventis Deutschlan...

1. An injection device for delivering a medicament to a patient, wherein the injection device comprises:
a housing;
a piston rod for driving a bung of a replaceable medicament container, the piston rod retractable to a backstop position;
a drive mechanism including a motor for providing an output drive to the piston rod for delivering a user settable dose of
the medicament and retracting the piston rod to the backstop position; and

a controller that controls operation of the device; wherein:
the controller comprises:
a drive signal generator that generates an input drive signal for the motor;
an encoder that generates an encoder output signal indicative of the output drive of the motor;
wherein the controller varies the operational control of the device in dependence on a comparison between the input drive
signal and the encoder output,

wherein the encoder output signal is a pulsed signal having a timing characteristic that corresponds to the output drive of
the motor,

wherein a comparison between counts of the encoder output with counts of stepper pulses is indicative of motor stall or motor
slip,

wherein the motor is deliberately stalled against a predetermined reference point when the quantum of slip exceeds a predetermined
threshold value, and

wherein the controller calculates the deficit in the medicament administered and performs administration of this dose.

US Pat. No. 9,242,045

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament, comprising
a housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing the medicament,
the housing having a distal end and a proximal end with an orifice intended to be applied against an injection site, wherein
the syringe is slidably arranged with respect to the housing,

a plunger connected to at least one of the syringe and the stopper,
a drive mechanism comprising at least one spring essentially transversally arranged with respect to a longitudinal axis of
the syringe at least when the drive mechanism is in a loaded state capable of, upon activation:

pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal
end, and

operating the syringe to supply the dose of medicament,
an activating mechanism arranged to lock the drive mechanism in the loaded state prior to manual operation and capable of,
upon manual operation, releasing the drive mechanism for injection, and

a linkage and cam mechanism configured to transmit movement of the drive mechanism into movement of the plunger, a linkage
of the linkage and cam mechanism comprising at least one arm with a first end and a second end, the first end having at least
one cam follower engaged in a cam track provided in the housing and being hinged to the at least one spring, the second end
being hinged to the plunger.

US Pat. No. 9,205,200

FINGER GUARD FOR AN INJECTION DEVICE

Sanofi-Aventis Deutschlan...

1. A finger guard for an injection device with a hollow injection needle arranged to be hidden inside a component with an
orifice prior to use and to be advanced relative to the component through the orifice for inserting it into an injection site,
a notch is arranged in a proximal most face of the component formed on a proximal end of the component near the orifice, the
finger guard comprising a spring wire attached to the component and comprising an arcuate transversal section biased in a
manner to flex inwards cantilevering into the orifice so as to essentially obstruct the orifice for finger access when released
but staying enough off-center to allow the needle to advance through the orifice without touching the spring wire, wherein
the notch locks the arcuate transversal section.
US Pat. No. 9,943,594

METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

SANOFI BIOTECHNOLOGY, Pa...

1. A method of treating rheumatoid arthritis in a subject previously ineffectively treated by administering methotrexate and previously ineffectively treated by administering a TNF-? antagonist, the method comprising administering to the subject(a) a therapeutically effective amount of methotrexate, and
(b) about 150 mg to about 200 mg of an antibody once every two weeks, wherein the antibody comprises a heavy chain variable region comprising the sequence SEQ ID NO:2 and a light chain variable region comprising the sequence SEQ ID NO:3 and the antibody is administered subcutaneously, wherein the subject achieves at least a 20% improvement in the American College of Rheumatology core set disease index (ACR20) after treatment.

US Pat. No. 9,663,524

SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES AS PROTEIN KINASE INHIBITORS

Celgene CAR LLC, Pembrok...

27. A composition comprising a compound according to claim 1, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

US Pat. No. 9,572,937

AUTOINJECTOR HAVING PISTON ROD WITH NON-CIRCULAR AXIAL BORE SLIDABLY ARRANGED ON HOUSING SHAFT TO PREVENT RELATIVE ROTATION

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament comprising:
a clutch mechanisms;
an elongate housing arranged to contain a syringe with a hollow needle and a bung for sealing the syringe and displacing the
medicament, the elongate housing having a distal end and a proximal end with an orifice intended to be applied against an
injection site, wherein the syringe is slidably arranged with respect to the housing,

a torsion spring capable of, upon activation, pushing the needle from a covered position inside the housing into an advanced
position through the orifice and past the proximal end as well as operating the syringe to supply the dose of medicament,
the torsion spring arranged around a tube,

a button arranged to lock the torsion spring in a pressurized state prior to manual operation and capable of, upon manual
operation, releasing the torsion spring for injection,

wherein the torsion spring is grounded at one end in the housing and at the other end in a first gear member, wherein a piston
rod is coupled to the bung in order to push it towards the proximal end, the piston rod having an axial bore for slidably
arranging the piston rod on a shaft attached to the housing, the axial bore and the shaft having corresponding non-circular
profiles, wherein the first gear member is engaged with the button prior to manual operation in a manner to prevent rotation
and wherein the first gear member is disengaged from the button upon manual operation, wherein a tube-shaped needle shroud
is arranged around the syringe in the housing, the needle shroud slideable between at least a drawn back position with a portion
of the needle shroud hidden inside the housing and an advanced position with more than the portion of the needle shroud protruding
from the proximal end and covering the hollow needle in its advanced position, wherein the needle shroud is biased by a second
spring towards the advanced position and locked in the drawn back position by a lock which is releasable by rotary movement
transmitted by the clutch mechanism which is engaged by the piston rod before the piston rod is fully advanced during an injection
stroke.

US Pat. No. 9,320,790

PHARMACEUTICAL COMPOSITIONS CONTAINING CLOSTRIDIUM DIFFICILE TOXOIDS A AND B

Sanofi Pasteur Biologics,...

1. A composition comprising:
(a) a toxoid of Clostridium difficile toxin A and/or B;

(b) a buffer selected from a citrate, phosphate, glycine, histidine, carbonate, bicarbonate, and HEPES buffer at a concentration
of 5-100 mM; and

(c) a sugar or sugar alcohol selected from sucrose, sorbitol, dextrose, and trehalose at a concentration of 1-30%;
wherein the pH of the composition is 5.5-8.0.
US Pat. No. 9,132,184

STABILIZATION OF VACCINES BY LYOPHILIZATION

Sanofi Pasteur Biologics,...

1. A freeze-dried composition comprising a live, attenuated flavivirus, one or more stabilizers, one or more buffer components, lactose, and amorphous mannitol.

US Pat. No. 10,503,994

DEVICE AND METHOD FOR PERFORMING OPTICAL CHARACTER RECOGNITION

Sanofi-Aventis Deutschlan...

1. A method of performing character isolation in an optical character recognition process, the method comprising:receiving image data representing one or more character columns;
determining a respective number of black pixels in each column in the one or more character columns of the image data;
defining a vertical separation threshold which is a maximum number of black pixels in a column;
dividing the character columns into different pixel groups and groups of excluded columns by excluding any column with the respective number of black pixels below the vertical separation threshold; and
identifying the pixel group representing a left most character column in the image data, further comprising:
identifying a left most group of excluded columns;
determining that a pixel group immediately to a right side of the left most group of excluded columns is below a minimum digit width threshold; and
excluding the pixel group immediately to the right side of the left most group of excluded columns.

US Pat. No. 9,427,531

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament, comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament, the housing having a distal end and a proximal end with an orifice intended to be applied against an injection
site, wherein the syringe is slidably arranged with respect to the housing,

a spring capable of, upon activation:
pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal
end,

operating the syringe to supply the dose of the medicament, and
retracting the syringe with the needle into the covered position after delivering the medicament,
an activating means arranged to lock the spring in a pressurized state prior to manual operation and capable of, upon manual
operation, releasing the spring for injection,

wherein the spring comprises a single drive spring in a shape of a compression spring arranged to be grounded in the housing
at a distal end of the drive spring for advancing the needle and for injecting the dose of the medicament via a plunger,

wherein a proximal end of the drive spring is grounded in the housing and the distal end of the drive spring is released from
its ground in the housing for retracting the syringe,

wherein a retraction sleeve is axially movable arranged in the housing, wherein the drive spring is arranged inside the retraction
sleeve with the distal end of the drive spring bearing against a distal end face of the retraction sleeve and with the proximal
end of the drive spring bearing against a thrust face of a decoupling member,

wherein at least one resilient decoupling arm is arranged at the decoupling member, the decoupling arm arranged for bearing
against a first shoulder of the plunger in a proximal direction,

wherein the resilient decoupling arm is supportable by an inner wall of the retraction sleeve in order to prevent the decoupling
arm from being flexed outward and slip past the first shoulder,

wherein at least one aperture is arranged in the retraction sleeve allowing the decoupling arms to be flexed outward by the
first shoulder thus allowing the first shoulder to slip past the decoupling arm in the proximal direction,

wherein the aperture extends at least almost to a position of the decoupling arms in an as delivered state,
wherein the aperture is arranged to be angularly misaligned with respect to the decoupling arm when the retraction sleeve
is in a proximal position, and

wherein the aperture is arranged to rotate so as to align with the decoupling arms upon translation of the retraction sleeve
out of the proximal position in a distal direction.

US Pat. No. 9,381,237

NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONS

Sanofi Pasteur Biologics,...

1. An isolated nucleic acid molecule encoding a protein comprising:
(a) a first region comprising a rhinovirus neutralizing immunogen IV (NimIV) peptide, wherein said NimIV peptide consists
of a sequence selected from the group consisting of: PVIKKR (SEQ ID NO:1), PVIKKRK (SEQ ID NO:2), PVIKKRE (SEQ ID NO:3), PVIKKRS
(SEQ ID NO:4), NTEPVIKKRKGDIKSY (SEQ ID NO:10), and an 8-30 amino acid fragment of the C-terminal end of virus structural
protein 1 (VP-1) of a human rhinovirus comprising one of said sequences; and

(b) contiguous flanking sequences that do not include sequences with which the first region is contiguous in a naturally occurring
virus.

US Pat. No. 9,192,716

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism for a drug delivery device, comprising:
a flexible advance cable bearing a coupling feature of longitudinal extension,
a guide means guiding the advance cable,
a drive means engaging the coupling feature and thus enabling an advancement of the advance cable according to the guide means,
wherein the drive means is provided for a permanent engagement with the coupling feature and where the drive means is a worm
or pinion, and the coupling feature is a screw thread, and

an end piece, which is provided to push a plug or bung of a cartridge containing a drug and which is driven by the advance
cable,

the advance cable is provided with balls having an outer diameter that exceeds an outer diameter of the advance cable and
corresponds to an inner diameter of the cartridge, and

the end piece is pushed by a portion of the advance cable that enters the cartridge.
US Pat. No. 9,132,181

MENINGOCOCCAL VACCINE BASED ON LIPOOLIGOSACCHARIDE (LOS) ORIGINATING FROM MODIFIED NEISSERIA MENINGITIDIS STRAINS OF IMMUNOTYPE L6

Sanofi Pasteur SA, Lyons...

1. A process of making a modified Neisseria meningitidis strain exhibiting a lipooligosaccharide (LOS) comprising a lipid A, an inner core, and an L6 type ? chain in which the heptose
II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent, wherein the process comprises
modifying an N. meningitidis strain of immunotype L6 so that it expresses its Ipt3 gene or the Ipt3 gene of a heterologous N. meningitidis strain and optionally does not express its lpt6 gene.

US Pat. No. 9,695,132

HETEROARYL COMPOUNDS AND USES THEREOF

Celgene CAR LLC, Pembrok...

1. A method for treating a FGFR4-mediated disorder in a patient in need thereof, comprising the step of administering to said
patient a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
X1 is NR4, N, CR4R4, or —CR4;

X2 is —NR5, N, —CR5R5, or —CR5;

X3 is N or CR6
X4 is N or CR7;

X5 is N, C, or CH; wherein at least one of X1, X2, X3, X4, or X5 is N;

G is H, O, OR, or N(R)(R);
Ring A is an optionally substituted group selected from a 3-8 membered saturated or partially unsaturated carbocyclic ring,
a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or a 7-10 membered bicyclic saturated, partially unsaturated or aryl ring;

each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 4-7 membered heterocyclic ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

two R groups on the same nitrogen are taken together with the nitrogen atom to which they are attached to form a 4-7 membered
heterocyclic ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 4-7 membered
heteroaryl ring having 0-4 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R1 is a warhead group -L-Y; wherein R1 is attached to an atom adjacent to the atom where T is attached, wherein:

R1 is selected from



 or
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are optionally
and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—; or

L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond and at least one methylene unit
of L is replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—, and one additional methylene unit of L is optionally replaced by cyclopropylene, —O—, —N(R)—, or —C(O)—;
or

L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one additional methylene
unit of L is replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—; or

L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two methylene units of L are optionally
and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—; and

the Y group of R1 is hydrogen, C1-6 aliphatic optionally with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups; or

L is a covalent bond, —CH2, —NH—, —C(O)—, —CH2NH—, —NHCH2—, —NHC(O)—, —NHC(O)CH2OC(O)—, —CH2NHC(O)—, —NHSO2—, —NHSO2CH2— or —SO2NH—, and the Y group of R1 is selected from:

(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN; or

(ii) C2-6 alkenyl substituted with oxo, halogen, NO2, or CN; or

(iii) C2-6 alkenyl optionally substituted with oxo, halogen, NO2, or CN; or

(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-2 Re groups; or

(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-4 Re groups; or

(vi)

 or
(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(x)

 or
(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(xii)

 or
(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Re groups; or

(xiv)

 or
(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein
said ring is substituted with 1-3 Re groups; or

(xvi)

 or
(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or

L is a covalent bond, —C(O)—, —N(R)C(O)—, or a bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain; and the Y group of R1 is selected from:

(i) C1-6 alkyl substituted with oxo, halogen, NO2 or CN; or

(ii) C2-6 alkenyl optionally substituted with oxo, halogen, NO2, or CN; or

(iii) C2-6 alkynyl optionally substituted with oxo, halogen, NO2, or CN; or

(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-2 Re groups; or

(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-4 Re groups; or

(vi)

 or
(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(x)

 or
(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(xii)

 or
(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Re groups; or

(xiv)

 or
(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein
said ring is substituted with 1-3 Re groups; or

(xvi)


 or
(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups;

each Re is independently selected from -Q-Z, oxo, NO2, halogen, CN, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a suitable leaving group selected from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally
substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, or diazonium, wherein:

Q is a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally
and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, —SO2—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO2—, or —SO2N(R)—; and

each Z is independently hydrogen or C1-6 aliphatic substituted with oxo, halogen, NO2 or CN;

each R2 is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;

R3 is hydrogen, C2-6 alkenyl, —W-Cy, or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, oxo, —OR?, or —C(O)O(C1-6 alkyl);

W is absent or is a bivalent C1-3 alkylene chain optionally substituted with one or more R? and wherein one methylene unit of W is optionally replaced with
—O—, —S—, or —NR?—;

each R? is independently hydrogen or C1-6 alkyl;

each R? is independently halogen or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, oxo, or —OR?;

Cy is phenyl, C3-7 cycloalkyl, or a 3-7 membered monocyclic or 5-10 membered bicyclic saturated, partially unsaturated, or heteroaryl ring having
1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Cy is optionally substituted with 1-3 Rx;

each Rx is independently H, —CN, oxo, —NH2, C1-6 alkyl, halogen, —OR, —N(R?)2, —NHC(O)(C1-6 alkyl), —C(O)N(R?)2, —C(O)O(C1-6 alkyl), —NHSO2(C1-6 alkyl), or —SO2N(R?)2;

or R3 is absent if not allowed by valence;

each of R4 and R4? is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-8 membered saturated or partially unsaturated carbocyclic ring which is optionally bridged, a 4-7 membered
heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic
heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-10 membered bicyclic
saturated, partially unsaturated or aryl ring, which is optionally bridged;

each of R5 and R5? is independently —R, halogen, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;

Y is O or NRa;

Ra is hydrogen or an optionally substituted C1-6 aliphatic group;

T is a covalent bond or a bivalent straight or branched, saturated or unsaturated C1-6 hydrocarbon chain wherein one or more methylene units are optionally replaced by —O—, —S—, —N(R)—, —C(O)—, —OC(O)—, —C(O)O—,
—C(O)N(R)—, —N(R)C(O)—, —N(R)C(O)N(R)—, —SO2—, —SO2N(R)—, —N(R)SO2—, or —N(R)SO2N(R)—;

q is 0-6; and
each of R6 and R7 is independently —R, halogen, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2.

US Pat. No. 9,440,029

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism for a drug delivery device, comprising:
a lead screw and a lead screw nut aligned with an axis defining an axial direction, and an opposite axial direction, and radial
directions diverging from the axis,

the lead screw comprising (i) a screw thread and (ii) at least one further screw thread, the screw thread and the at least
one further screw thread having the same pitch and being intertwined, and

a drive feature of the lead screw nut, the drive feature comprising three angularly equi-spaced drive portions;
the drive feature engaging the screw thread and the further screw thread and allowing for a dispense operation of a fixed
dose,

the dispense operation comprising a helical movement of the lead screw with respect to the lead screw nut at least in the
axial direction,

the lead screw advancing a piston in a distal direction.

US Pat. No. 9,352,098

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A drive mechanism for a drug delivery device, comprising:
a body having a distal end and a proximal end, spaced apart in the direction of a first axis and a second axis that is parallel
to the first axis,

a first input member and a second input member, arranged within the body along the first axis and coupled in such a manner
that a movement of the first input member along the first axis is converted into a rotational movement of the second input
member with respect to the body,

a first output member and a second output member, arranged within the body along the second axis and coupled in such a manner
that a rotational movement of the first output member is converted into a movement of the second output member along the second
axis with respect to the body,

the second input member and the first output member being releasably rotationally coupled when the first input member is moved
in a distal direction,

a pinion member releasably rotationally coupling the second input member and the first output member,
a pawl member engaging with the pinion member allowing rotation of the pinion member in only one direction, and
a clutch coupling the second input member with the pinion member in a releasable fashion such that the clutch couples the
second input member with the pinion member when a force is exerted on the first input member in the distal direction, and
the second input member and the pinion member are not coupled when the first input member is being shifted in a proximal direction.

US Pat. No. 9,217,158

REPLICATION-DEFECTIVE FLAVIVIRUS VACCINES AND VACCINE VECTORS

Sanofi Pasteur Biologics,...

1. A replication-deficient pseudoinfectious flavivirus comprising a West Nile virus genome comprising (i) one or more deletions
in nucleotide sequences encoding capsid (C) protein, and deletion of the nucleotide sequences encoding pre-membrane (prM)
and/or envelope (E) proteins, and (ii) a sequence encoding a heterologous immunogen inserted in place of or in combination
with said deletion of the prM and/or E nucleotide sequences,
wherein the heterologous immunogen is from a pathogen selected from the group consisting of a rabies virus, influenza virus,
respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV).

US Pat. No. 9,120,812

PYRIMIDOOXAZOCINE DERIVATIVES AS MTOR-INHIBITORS

Sanofi, Paris (FR)

1. A compound of formula (I):
wherein:
each R1 is independently (C1-C6)-alkyl, wherein two R1 groups on different carbon atoms of the morpholinyl ring may be linked together to form, with the morpholinyl ring, a bicyclic
heterocyclic structure;

R2 and R3 are independently hydrogen or (C1-C6) alkyl;

R4 is hydrogen, (C1-C6) alkyl optionally substituted with a hydroxyl group, (C1-C6)-alkoxy or -L1-R10, wherein

L1 is (C1-C6)-alkylene, and

R10 is —COOR11, —CO—R12, —OR13, —CONR14R15, a 5- or 6-atom heterocycle optionally substituted with —R16, —COOR17, —CO—R18, —OR19 or —NR20R21, or a 5- or 6-atom heterocycle optionally substituted with —R22, —COOR23, —CO—R24, —OR25 or —CONR26R27, wherein each 5- or 6-atom heterocycle is saturated, partially unsaturated or aromatic, and includes one or more heteroatoms
selected from O, N and S;

G1 is phenylene or a 5- to 6-atom heteroarylene, optionally substituted with 1 to 4 R5 groups, each R5 group being independently chosen from halogen, —OR30 and —(C1-C6)-alkyl optionally substituted with hydroxyl;

X1 is —O— or —NR40—;

X2 is a single bond, —CONR50—, —CONR51—O—, —COO—, —CO— or —SO2—;

R6 is hydrogen or -L2-R7, wherein

-L2- is (C1-C6)-alkylene or (C3-C6)-cycloalkylene;

R7 is hydrogen, —OR60, halogen, (C1-C6)-haloalkyl, a 5- to 6-atom heterocycle optionally substituted with one or more groups chosen from (C1-C6)-alkyl, (C1-C6)-alkoxy and ?O, or -G2-X3-G3, wherein:

X3 is a single bond or —O—, —CO— or —CH2—;

G2 is a single bond or a 5- to 6-atom divalent cyclic radical optionally substituted with one or more R80,

G3 is a 4- to 8-atom ring optionally substituted with one or more R81, or -G2-X3-G3 together form a 7- to 10-atom fused bicycle, wherein

each R80 and R81 is independently halogen, —COOR70, —CO—R71, —OR72,—NR73R74, —CONR75R76, —CN or —S(O)p—R77,

(C1-C6)-alkyl optionally substituted with one or more R100 groups, and/or optionally interrupted with one or more oxygen atoms, and

(C1-C6)-alkoxy optionally substituted with one or more R101 groups, and/or optionally interrupted with one or more oxygen atoms,

n is 0, 1 or 2;
m is 0 or 1;
p is 0, 1 or 2;
R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R30, R40, R50, R51, R60, R70, R71, R72, R73, R74, R75, R76 and R77 are independently H or (C1-C6)-alkyl optionally substituted with a R90 group, and/or optionally interrupted with one or more oxygen atoms;

R90 is —OR91 or —NR92R93;

R91, R92 and R93 are independently hydrogen or (C1-C6)-alkyl; and

R100 and R101 are independently halogen or hydroxyl;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 9,073,914

SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES

SANOFI, Paris (FR) MITSU...

5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof and one or more pharmaceutical additives.

US Pat. No. 9,073,915

SUBSTITUTED PYRIMIDONE DERIVATIVES

SANOFI, Paris (FR) MITSU...

1. A compound of formula (I):
wherein:
R1 represents a 4-pyridine ring;
R2 represents a hydrogen atom;
R3 represents a hydrogen atom;
R4 represents:
a hydrogen atom, or
a phenyl ring which is optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, and a C1-2 halogenated alkoxy group;

R5 represents a hydrogen atom, a C1-6 alkyl group, a 4-pyridine group, or a phenyl group, these groups being optionally substituted by 1 to 4 substituents selected
from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, and a C1-2 halogenated alkoxy group;

R6 represents a hydrogen atom, a C1-6 alkyl group, a benzyloxy group, or a phenyl-C1-6 alkyl group, these groups being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, and a C1-2 halogenated alkoxy group;

or an acid addition salt thereof;
with the proviso that when R4 and R5 represent a hydrogen atom, R6 is not methyl or benzyl.

US Pat. No. 9,457,152

DRIVE MECHANISM FOR A MEDICATION DELIVERY DEVICE AND MEDICATION DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism for a medication delivery device, comprising:
a housing having a proximal end and a distal end,
a rotation member which is adapted to be rotated in a first direction with respect to the housing during setting of a dose
of a medication and to be rotated in a second direction with respect to the housing during delivery of the dose, the second
direction being opposite to the first direction,

a piston rod which is adapted to be displaced in a distal direction with respect to the housing for delivering the dose,
a drive member which follows rotational movement of the rotation member in the second direction during delivery of the dose,
and

a stop member which prevents rotational movement of the drive member with respect to the housing in the first direction during
setting of the dose,

wherein the rotational movement of the drive member in the second direction is converted into movement of the piston rod in
the distal direction with respect to the housing,

wherein the drive member abuts the rotation member during movement of the rotation member for setting and delivery of the
dose.

US Pat. No. 9,447,038

SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS

Sanofi, Paris (FR)

1. A compound of formula 1

wherein
R represents hydrogen, —C1-4 alkyl, —C3-8 cycloalkyl, —C1-4 halogenalkyl or halogenphenyl group;

R? represents hydrogen or
R and R? represent together with the carbon atom attached a C4 aliphatic ring; and

R1 represents a group selected from the group consisting of


wherein
A represents a direct bond or CH2, CH(CH3), C(CH3)2 or C(CH2)2 group;

R2 represents Cl, Me or —CF3;

R3 represents hydrogen, Cl or F;

R4 represents hydrogen or a —C1-4 alkyl group;

R5 represents a heteroaryl group selected from the group consisting of


X represents O, S or CH2 ;

Y represents hydrogen, halogen or a —C1-4 alkyl, —C1-4 alkoxy or —C1-4 hydroxyalkyl group; and

Z represents a C1-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, NH and
N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge optionally containing N fused with a C3-6 cycloalkyl ring optionally containing one or more double bonds or with a phenyl ring or represents a C1-4 aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bonds;

or a pharmaceutically acceptable salt thereof, stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.

US Pat. No. 9,393,368

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism for a drug delivery device, comprising:
a body having a proximal end and a distal end,
a piston rod arranged within the body along an axis of rotation,
a dose member having a thread, the thread engaging a corresponding thread of the body to allow a helical movement of the dose
member with respect to the body, the helical movement comprising a rotation around the axis and a simultaneous shift along
the axis,

a drive sleeve arranged within the body, rotatable with respect to the body around the axis and rotationally coupled to the
dose member,

a proximal stop interface provided to restrict a movement of the drive sleeve in the proximal direction with respect to the
body,

a distal stop interface provided to restrict a movement of the drive sleeve in the distal direction with respect to the body,
a stop member arranged within the body and being rotationally locked to the body with respect to the axis and being axially
movable with respect to the body along the axis,

a drive member arranged within the body, the drive member being rotationally locked to the piston rod and held in contact
with the stop member,

a first gear locking the drive member unidirectionally rotationally to the stop member in a first sense of rotation with respect
to the body, and

a second gear locking the drive member rotationally to the drive sleeve when the drive sleeve is rotated in a second sense
of rotation, which is opposite to the first sense of rotation, with respect to the body.

US Pat. No. 9,352,097

SPINDLE FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A dose setting mechanism for use with a drug delivery device comprising a housing, a clutch, a number sleeve, an inner
housing, a spindle for driving a bung of a cartridge and further comprising a driver for driving said spindle, which extends
about the spindle, with said driver comprising a helical groove form that engages a first helical groove of said spindle,
said spindle comprising:
a generally circular shaft having an outer surface, said generally circular shaft extending from a distal end to a proximal
end of said circular shaft;

a first helical groove provided along a first portion of said outer surface of said generally circular shaft, said first helical
groove having a first pitch; and

a second helical groove provided along a second portion of said outer surface of said generally circular shaft, said second
helical groove overlapping said first helical groove, said second helical groove having a second pitch;

wherein the number sleeve is in rotatable engagement with respect to said housing;
wherein the driver is releasably coupled to said number sleeve with the clutch disposed about the driver between the driver
and the number sleeve; and

wherein the spindle is operatively coupled to said driver, such that when a user sets a dose by rotating said number sleeve,
said driver also rotates,

wherein the inner housing fits between the clutch and the number sleeve.

US Pat. No. 9,314,577

NEEDLE HUB AND VALVE FOR NEEDLE HUB

SANOFI-AVENTIS DEUTSCHLAN...

1. An apparatus comprising:
a valve body comprising a first inlet opening, a second inlet opening, an outlet opening, and a central space connecting the
first inlet opening, the second inlet opening, and the outlet opening, and

a spherical element movably contained inside the central space configured for translatory movement and configured to seal
either the first inlet opening or the second inlet opening,

wherein the first inlet opening and the second inlet opening are configured for fluid communication with a first reservoir
and a second reservoir, respectively,

wherein the outlet opening is configured for fluid connection with a septum.

US Pat. No. 9,089,678

METHOD AND APPARATUS FOR PENETRATING TISSUE

SANOFI-AVENTIS DEUTSCHLAN...

1. A body fluid sampling system for use on a tissue site, the system comprising:
an electrically powered drive force generator;
a plurality of cartridges each containing a penetrating member, each of said cartridges coupled together to define a flexible
array;

a transport device for moving each of said cartridges into a launch position operatively coupling said penetrating member
to the force generator;

a processor coupled to the electrically powered drive force generator, the processor configured to customize a profile and
in response modulate power to the electrically powered drive force generator; and

a flexible support member coupling said cartridges to define a linear array, said support member being movable and configured
to move each of said cartridges to said launch position associated with said force generator.

US Pat. No. 9,078,973

DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device, comprising
an outer housing rollable around a rotation axis and at least one stop member, wherein the stop member protrudes radially
from the outer housing of the drug delivery device and wherein the stop member is configured to prevent rolling movement of
the drug delivery device along a predetermined surface, wherein the outer housing comprises a main housing and a dose member,
wherein the dose member is configured to abut the main housing in an initial state and to move proximally a distance away
from the main housing to set a dose and then to move distally to deliver the set dose and wherein the stop member comprises
a first part and a second part, wherein the first part is arranged on the main housing and the second part is arranged on
the dose member such that during dose setting the second part moves proximally relative to the first part and wherein the
second part is aligned with the first part so that the second part is configured to continue a shape of the first part of
the stop member when the dose member is in an initial state before the dose is set.

US Pat. No. 9,456,845

NEEDLE ASSEMBLY SYSTEM

Sanofi-Aventis Deutschlan...

1. A needle assembly system comprising:
a medicament delivery device; and
a needle assembly mountable on a distal portion of the medicament delivery device, the needle assembly comprising:
a needle;
a needle hub adapted to carry the needle, wherein the needle hub includes:
a proximal portion adapted to engage the medicament delivery device; and
a cover portion adapted to abut a distal surface of the medicament delivery device,
wherein the proximal portion of the needle hub includes a second thread adapted to engage a first thread of the medicament
delivery device,

wherein the second thread is offset from the cover portion by a first distance, the first thread extends along the distal
portion of the medicament delivery device for a second distance, and the first distance is substantially equivalent to the
second distance,

wherein the distal portion of the medicament delivery device comprises (i) an unthreaded region extending proximally from
the first thread or (ii) a threaded region extending proximally from the first thread and having a third thread with a depth
less than a depth of the first thread, and

wherein the first thread is configured to be threadedly disengaged from the needle assembly and the second thread is configured
to be positioned over the unthreaded region or the threaded region of the distal portion of the medicament delivery device
when the needle assembly is mounted on the medicament delivery device.

US Pat. No. 9,441,040

ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF

Sanofi, Paris (FR)

1. A method for treating thrombotic or vascular diseases, the method comprising administering to a subject an antibody Fab
fragment that specifically binds to human platelet membrane protein Glycoprotein VI (GPVI) and induces a GPVI depletion phenotype,
wherein the antibody Fab fragment binds to a conformational epitope of human GPVI and contacts human GPVI amino acid residues
Ser 43, Arg 67, and Asp 81.

US Pat. No. 9,321,786

HETEROARYL COMPOUNDS AND USES THEREOF

Celgene Avilomics Researc...

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:
X1 is —NR4, N, —CR4R4?, or —CR4;

X2 is —NR5, N, —CR5R5?, or —CR5;

X3 is N or CR6
X4 is N or CR7;

X5 is N, C, or CH; wherein at least one of X1, X2, X3, X4, or X5 is N;

G is H, O, OR, or N(R)(R);
Ring A is an optionally substituted group selected from a 3-8 membered saturated or partially unsaturated carbocyclic ring,
a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or a 7-10 membered bicyclic saturated, partially unsaturated or aryl ring;

each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 4-7 membered heterocyclic ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

two R groups on the same nitrogen are taken together with the nitrogen atom to which they are attached to form a 4-7 membered
heterocyclic ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 4-7 membered
heteroaryl ring having 0-4 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R1 is a warhead group -L-Y; wherein R1 is attached to an atom adjacent to the atom where T is attached, wherein:

R1 is selected from


 or
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are optionally
and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—; or

L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond and at least one methylene unit
of L is replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—, and one additional methylene unit of L is optionally replaced by cyclopropylene, —O—, —N(R)—, or —C(O)—;
or

L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one additional methylene
unit of L is replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—; or

L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two methylene units of L are optionally
and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—; and

the Y group of R1 is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups; or

L is a covalent bond, —CH2—, —NH—, —C(O)—, —CH2NH—, —NHCH2—, —NHC(O)—, —NHC(O)CH2OC(O)—, —CH2NHC(O)—, —NHSO2—, —NHSO2CH2, or —SO2NH—, and the Y group of R1 is selected from:

(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN; or

(ii) C2-6 alkenyl substituted with oxo, halogen, NO2, or CN; or

(iii) C2-6 alkynyl optionally substituted with oxo, halogen, NO2, or CN; or

(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-2 Re groups; or

(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-4 Re groups; or

(vi)

 or
(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(x)

 or
(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(xii)

 or
(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Re groups; or

(xiv)

 or
(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein
said ring is substituted with 1-3 Re groups; or

(xvi)

 or
(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or

L is a covalent bond, —C(O)—, —N(R)C(O)—, or a bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain; and the Y group of R1 is selected from:

(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN; or

(ii) C2-6 alkenyl optionally substituted with oxo, halogen, NO2, or CN; or

(iii) C2-6 alkynyl optionally substituted with oxo, halogen, NO2, or CN; or

(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-2 Re groups; or

(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is
substituted with 1-4 Re groups; or

(vi)

 or
(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or

(x)

 or
(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen,
or sulfur, wherein said ring is substituted with 1-4 Re groups; or

(xii)

 or
(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Re groups; or

(xiv)

 or
(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein
said ring is substituted with 1-3 Re groups; or


 or
(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups;

each Re is independently selected from -Q-Z, oxo, NO2, halogen, CN, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a suitable leaving group selected from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally
substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, or diazonium, wherein:

Q is a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally
and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, or —SO2—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO2—, or —SO2N(R)—; and

each Z is independently hydrogen or C1-6 aliphatic substituted with oxo, halogen, NO2, or CN;

each R2 is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;

R3 is hydrogen, C2-6 alkenyl, -W-Cy, or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, oxo, —OR?, or —C(O)O(C1-6 alkyl);

W is absent or is a bivalent C1-3 alkylene chain optionally substituted with one or more R? and wherein one methylene unit of W is optionally replaced with
—O—, —S—, or —NR?—;

each R? is independently hydrogen or C1-6 alkyl;

each R? is independently halogen or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, oxo, or —OR?;

Cy is phenyl, C3-7 cycloalkyl, or a 3-7 membered monocyclic or 5-10 membered bicyclic saturated, partially unsaturated, or heteroaryl ring having
1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Cy is optionally substituted with 1-3 Rx;

each Rx is independently H, —CN, oxo, —NH2, C1-6 alkyl, halogen, —OR?, —N(R?)2, —NHC(O)(C1-6 alkyl), —C(O)N(R?)2, —C(O)O(C1-6 alkyl), —NHSO2(C1-6 alkyl), or —SO2N(R?)2;

or R3 is absent if not allowed by valence;

each of R4 and R4? is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-8 membered saturated or partially unsaturated carbocyclic ring which is optionally bridged, a 4-7 membered
heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic
heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-10 membered bicyclic
saturated, partially unsaturated or aryl ring, which is optionally bridged;

each of R5 and R5? is independently —R, halogen, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;

Y is O or NRa;

Ra is hydrogen or an optionally substituted C1-6 aliphatic group;

T is a covalent bond or a bivalent straight or branched, saturated or unsaturated C1-6 hydrocarbon chain wherein one or more methylene units are optionally replaced by —O—, —S—, —N(R)—, —C(O)—, —OC(O)—, —C(O)O—,
—C(O)N(R)—, —N(R)C(O)—, —N(R)C(O)N(R)—, —S(O)—, —SO2—, —SO2N(R)—, —N(R)SO2—, or —N(R)SO2N(R)—;

q is 0-6; and
each of R6 and R7 is independently —R, halogen, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2.

US Pat. No. 9,145,543

PROCESS FOR CULTURING ADHERENT CELLS

Sanofi Pasteur SA, Lyons...

1. A process for producing adherent cells comprising:
a) introducing a suspension of adherent cells into a culture vessel containing microcarriers in a culture medium, wherein
the culture vessel is in direct physical contact with the culture medium;

b) amplifying the cells by performing a plurality of cell passages in the same culture vessel, wherein each cell passage subsequent
to the first cell passage is carried out:

i) by retaining in the culture vessel all or part of the cells produced during the previous cell passage after having subjected
the cells to enzyme treatment in the culture vessel to detach the cells from microcarriers without removing the all or part
of the cells produced during the previous cell passage from the culture vessel, and

ii) by introducing culture medium and an increasing amount of microcarriers into the culture vessel; and
c) harvesting the cells produced during the last cell passage, optionally after having subjected the cells to enzyme treatment
to detach cells from microcarriers.

US Pat. No. 9,108,007

SPINDLE AND BEARING COMBINATION AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A spindle and bearing combination for use in a drug delivery device comprising,
a) a rotatable spindle having a distal end; and
b) a disk-shaped bearing configured to abut a proximal face of a non-rotatable piston in a medicament container, where the
disk-shaped bearing has a first connection and a second connection to the distal end of the spindle, where the first connection
comprises a web that fixedly attaches the disk-shaped bearing to the spindle to prevent independent movement of the disk-shaped
bearing relative to the spindle and where the second connection is created and replaces the first connection when the web
is sheared such that the spindle is rotatably connected to the disk-shaped bearing and the distal end of the spindle is retained
within the disk-shaped bearing by a pair of cooperating web shears formed from the sheared web.

US Pat. No. 9,623,190

PEN-TYPE INJECTOR

Sanofi-Aventis Deutschlan...

1. A drug delivery device comprising:
a first member comprising (i) a first thread, (ii) a dose dispensing end, and (iii) a stop member that is integral to the
first member;

a second member disposed radially inward from the first member, the second member comprising a second thread that engages
with the first thread;

a third member disposed radially inward from the second member;
a fourth member disposed radially inward from the third member;
a fifth member engaged with the fourth member, the fifth member comprising a third thread;
a sixth member that is rotationally fixed to the fourth member;
wherein:
the stop member is configured to engage the second member and prevent axial movement of the sixth member away from the dose
dispensing end;

the third member is configured to be rotationally fixed to the second member during dose setting;
the fourth member is configured to be rotationally fixed to the third member during dose setting;
the second, third, and fourth members configured to rotate during dose setting;
the fifth member configured to traverse axially during dose dispensing;
the sixth member is configured to be depressed axially towards the dose dispensing end.

US Pat. No. 9,561,000

METHOD AND APPARATUS FOR IMPROVING FLUIDIC FLOW AND SAMPLE CAPTURE

Sanofi-Aventis Deutschlan...

1. A body fluid sampling device for use on a patient, comprising:
a cartridge;
at least one penetrating member positioned in the cartridge;
a sample port for receiving a body fluid in response to a puncturing event by the at least one penetrating member;
a sample chamber that includes an analyte detecting member;
a channel coupled to the sample port and the sample chamber, at least a portion of the channel being a capillary channel positioned
adjacent to the sample chamber;

a mesh membrane that provides body fluid transport and positioned in the channel and at the sample port or adjacent to the
sample port to guide a flow of the body fluid through at least a portion of the capillary channel with the mesh providing
that the body fluid contacts the channel regardless of an orientation of body fluid sampling device, the mesh being positioned
to provide that the mesh does not disrupt a path of a penetrating member as it passes from the cartridge and is pushed aside
from the penetrating member creating a ring of capillary fibers around a wound channel that is available after the penetrating
member is retracted to wick the body fluid into the channel; and

an adhesive integrated with the mesh membrane for defining a flow channel within the mesh membrane structure, the adhesive
prohibiting fluidic flow where flow is not desired, sealing the flow channel from lateral flow leaks and providing an enhancement
for fluid flow in the flow channel.

US Pat. No. 9,408,977

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A drive mechanism for a drug delivery device, comprising:
a housing,
a piston rod arranged inside the housing,
a drive member arranged inside the housing, the drive member being rotatable with respect to the housing,
a rotation member rotatable with respect to the housing,
a dose member, which is movable between a first axial position with respect to the housing and a second axial position that
is axially spaced from the first axial position,

an engagement of the dose member with the housing, the engagement allowing the dose member to move according to a set/deliver
path between the first axial position and the second axial position in either direction or to move according to a cancel path
from the second axial position to the first axial position, and

an engagement of the dose member with the rotation member and a unidirectional rotational engagement of the rotation member
with the drive member by a clutch in such a manner that the rotation member is rotated when the dose member is moved according
to the set/deliver path and the drive member is not rotated when the dose member is moved according to the cancel path,

wherein the piston rod comprises a thread engaged with the housing such that a rotational movement of the piston rod is converted
into a movement of the piston rod with respect to the housing in a distal direction,

wherein the piston rod comprises a track engaged with the drive member such that an axial movement of the piston rod relative
to the drive member is allowed and a rotational movement of the drive member with respect to the housing is converted into
a rotational movement of the piston rod with respect to the housing, and

wherein the dose member is threadedly engaged with the rotation member.

US Pat. No. 9,402,962

ASSEMBLY FOR USE IN A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. An assembly for a drug delivery device comprising a proximal end, a distal end, a moveable member, a dose member, a fixed
member and a coupling means,
wherein in a first state, (i) the moveable member is moveable in an axial direction with respect to the fixed member and the
dose member and (ii) the coupling means retains the dose member to the fixed member by interacting with both the dose member
and the fixed member to form a connection between the dose member and the fixed member, and

wherein in a second state of the assembly, (i) the coupling means (a) permanently connects the moveable member with the dose
member and (b) releases the connection between the dose member and the fixed member formed by the coupling means and (ii)
the assembly is configured to set and dispense a dose of a fluid medicinal product out of an assembled cartridge by movement
of the dose member.

US Pat. No. 9,375,535

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A resettable drive assembly for a drug delivery device comprising
a housing having a proximal end and a distal end;
a piston rod being rotatable with respect to the housing and being axially displaceable with respect to the housing between
a proximal start position and a distal end position;

a drive member for distally displacing the piston rod towards the end position when dispensing a dose; and
a stop member;
wherein the drive assembly is configured such that
the drive member is operable to interact with the piston rod for forming an unlockable first interlock, the first interlock
being operable to block proximal movement of the piston rod with respect to the drive member;

the stop member is operable to interact with the piston rod for forming an unlockable second interlock, the second interlock
being operable to block proximal movement of the piston rod with respect to the housing;

when the drive assembly is in a drive mode, the first and second interlocks are locked such that proximal movement of the
piston rod from the end position to the start position is prevented by the first interlock and the second interlock;

for switching the drive assembly from the drive mode to a reset mode, the piston rod is rotatable with respect to the drive
member for unlocking the first interlock and the stop member and the piston rod are rotatable with respect to each other for
unlocking the second interlock; and

when the drive assembly is in the reset mode, the first interlock and the second interlock are unlocked such that proximal
movement of the piston rod to the start position is allowed.

US Pat. No. 9,370,623

DRIVE ASSEMBLY FOR A MEDICATION DELIVERY DEVICE AND MEDICATION DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive assembly for a medication delivery device, comprising
a piston rod movable from a start position to an end position for medication delivery and resettable from the end position
to the start position,

a guide member being in engagement with the piston rod;
a body part; and
an impeding element for impeding a movement of the guide member during a reset of the piston rod, thereby impeding the reset
of the piston rod,

wherein during a movement of the piston rod towards the end position the guide member is rotationally fixed with respect to
the body part,

wherein during the reset of the piston rod towards the start position the guide member is rotationally movable with respect
to the body part.

US Pat. No. 9,272,098

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. Auto-injector for administering a dose of a liquid medicament (M), comprising:
a substantially cylindrical housing arranged to contain a pre-filled syringe with an injection needle, a plunger and a stopper
for sealing a syringe barrel and

a driver releasably coupled to the plunger for advancing the syringe in the proximal direction (P) for needle insertion into
an injection site and for displacing the dose of medicament (M) into the injection site,

wherein the driver is arranged to be decoupled from the plunger for advancing a needle shroud to a safe position (PS) to surround
the injection needle after the injection,

wherein the driver bears against a thrust collar arranged to be releasably coupled to the plunger through a ramped engagement
so as to rotate the thrust collar on translation in proximal direction (P), wherein guiding mechanism are provided for guiding
the thrust collar during at least a part of its axial translation when inserting the needle and displacing the medicament
(M) to prevent a rotation of the thrust collar, wherein the thrust collar is arranged to rotate out of engagement to the plunger
on removal of the auto-injector from the injection site.

US Pat. No. 9,144,649

DOSE SETTING MECHANISM AND INJECTION DEVICE

SANOFI-ADVENTIS DEUTSCHLA...

1. A dose setting mechanism for a drug delivery device, the mechanism comprising:
a dose setting member,
a drive member,
a clutch member located between the dose setting member and the drive member, the clutch member being axially movable relative
to the dose setting member and to the drive member and being rotationally fixed to the drive member, providing a first clutch
for rotationally coupling and de-coupling the dose setting member and the drive member,

a clicker comprising a first clicker component and a second clicker component axially movable relative to each other for producing
a tactile and/or audible feedback during dose setting of the drug delivery device,

wherein the first clicker component is axially movable relative to the drive member providing a second clutch for rotationally
coupling and de-coupling the drive member and the first clicker component,

wherein the first clutch and the second clutch are designed and adapted to each other such that at any time during operation
either the first clutch rotationally couples the dose setting member and the drive member and/or the second clutch rotationally
couples the drive member and the first clicker component.

US Pat. No. 9,072,836

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drive mechanism for a drug delivery device, comprising:
a lead screw, a lead screw nut and a drive member, aligned with an axis defining an axial direction and an opposite axial
direction,

a coupling between the lead screw and the lead screw nut allowing a helical movement of the lead screw with respect to the
lead screw nut at least in the axial direction,

the lead screw being coupled with the drive member, the coupling of the lead screw with the drive member generating a helical
movement of the lead screw with respect to the drive member when the drive member is moved in the axial direction with respect
to the lead screw, and the coupling of the lead screw with the drive member being overridden to prevent a helical movement
of the lead screw with respect to the drive member when the drive member is moved in the opposite axial direction with respect
to the lead screw,

a dispense stop feature of the lead screw nut, and
a dispense stop feature of the drive member,
the dispense stop features interacting and thereby preventing the generation of the helical movement of the lead screw when
the drive member approaches a specified end position of dispense, wherein the dispense stop features guide the drive member
with respect to the lead screw nut in a helical movement having the same pitch as the helical movement of the lead screw with
respect to the drive member.

US Pat. No. 9,067,018

CARTRIDGE HOLDER ASSEMBLY FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. Cartridge holder assembly for a drug delivery device comprising:
a cartridge holder adapted to receive a cartridge to be filled with a medicinal product to be dispensed by the drug delivery
device, wherein the cartridge holder comprises at least one through opening at a distal end section to receive a piercing
element being adapted to penetrate a sealing septum of the cartridge,

a constriction member comprising one or more displaceable and/or pivotable retention elements and adapted to axially abut
against the septum and form a through opening to receive the piercing element, wherein said through opening is adjustable
in diameter.

US Pat. No. 9,662,454

RESETTING MECHANISM FOR A DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A resettable dose setting mechanism for a drug delivery device comprising:
a spindle;
a rotating sleeve in rotatable engagement with respect to housing; and
a driver for driving the spindle of the drug delivery device in a distal direction to cause a distal end of the spindle to
act on a bung within a cartridge,

wherein said driver comprises a first component and a second component rotationally coupled to said first component,
wherein during resetting of said drug delivery device, said first component is decoupled from said second component such that
the first component can rotate relative to the second component causing the spindle to retract axially in a proximal direction,

wherein during a dose setting operation a user rotates the rotating sleeve causing the first component and the second component
of the driver to rotate together,

wherein the resettable dose setting mechanism is designed such that the first component and the second component remain locked
together rotationally during the dose setting operation as well as during dose administration and

wherein during the dose setting operation the first and second components are coupled together to rotate together in unison
relative to the housing and the spindle causing the driver to move axially in the proximal direction when the user dials a
dose of medicament for administration.

US Pat. No. 9,517,310

PEN INJECTOR WITH RESETTING MECHANISM FOR RECEIVING NEW CARTRIDGE DURING DRIVER DECOUPLING AND PROXIMAL SPINDLE RETRACTION

SANOFI-AVENTIS DEUTSCHLAN...

1. A resettable dose setting mechanism for a drug delivery device comprising a driver for driving a spindle of the drug delivery
device device in a distal direction to cause a distal end of the spindle to act on a bung within a cartridge, said driver
comprising a first component and a second component rotationally coupled to said first component, wherein during resetting
of said drug delivery device, that is during preparation of the dose setting mechanism for receiving a new cartridge, said
first component is decoupled from said second component such that the first component can rotate relative to the second component,
wherein during a dose setting operation the first and second components are coupled together to rotate together in unison
relative to an outer housing and the spindle when a user dials a dose of medicament for administration causing the driver
to move axially in a proximal direction,

the dose setting mechanism further comprising a dose limiter wherein during resetting of said drug delivery device to add
the new cartridge, said dose limiter is reset to an initial position and the spindle retracts axially in the proximal direction.

US Pat. No. 9,402,961

DRUG DELIVERY DEVICE HAVING A SPRING ELEMENT

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device comprising:
a variable dose setting mechanism operably coupled to a first reservoir holding a first medicament, the variable dose setting
mechanism having a dose setter;

a fixed dose setting mechanism operably coupled to a second reservoir holding a second medicament;
a mechanical coupling, wherein the mechanical coupling operably couples the variable dose setting mechanism and the fixed
dose setting mechanism and wherein the mechanical coupling comprises a spring element;

wherein the variable dose setting mechanism is configured to set a variable dose of the first medicament upon activation of
the dose setter,

wherein the fixed dose setting mechanism is configured to set a fixed dose of the second medicament during the activation
of the dose setter, and

wherein the spring element is configured to store energy during dose setting and to transfer stored energy to the fixed dose
setting mechanism to at least assist with dispense of the fixed dose.

US Pat. No. 9,393,360

NEEDLE ASSEMBLY STORAGE DEVICE

Sanofi-Aventis Deutschlan...

1. A needle assembly storage device, the storage device comprising:
a container;
a pocket formed in the container;
a needle assembly received in the pocket;
a pull linkage comprising an end portion defining a predetermined breaking point connecting the needle assembly to the container,
the predetermined breaking point being configured to break to disconnect the needle assembly from the container when a sufficient
rotational force is applied to the needle assembly in a first direction; and

a projection on the needle assembly configured to limit rotation of the needle assembly in the pocket in a second direction
opposite to the first direction when the pull linkage is disengaged from the needle assembly.

US Pat. No. 9,386,944

METHOD AND APPARATUS FOR ANALYTE DETECTING DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. An integrated analyte measurement system, comprising:
a housing;
a disposable configured to be positioned in the housing;
a plurality of penetrating members positioned in the disposable;
a driver configured to be coupled to the penetrating member, the driver coupled to a processor and having position and velocity
sensing capabilities to advance a penetrating member into a target tissue to create a wound from which body fluid will flow,
the processor and driver providing control of drive power to a penetrating member and velocity of the penetrating member to
account for variations in a skin thickness during advance of the penetrating member to create the wound; and

a plurality of analyte sensors positioned in the disposable, the disposable housing used and unused penetrating members as
well as analyte sensors.

US Pat. No. 9,352,090

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament, comprising:
a tubular chassis,
a carrier subassembly comprising a tubular carrier slidably arranged partially inside the chassis, the carrier adapted to
contain a syringe with a hollow injection needle, a drive spring and a plunger for forwarding load of the drive spring to
a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier,

a control spring arranged around the carrier,
a needle insertion control mechanism for coupling a proximal end of the control spring to either the carrier for advancing
it for needle insertion or to the chassis for needle retraction depending on the relative axial position of the carrier and
the chassis,

wherein the needle insertion control mechanism comprises a first collar biased by the control spring in a proximal direction,
wherein at least one resilient beam is proximally arranged on the first collar, wherein respective recesses are arranged in
the carrier and chassis, wherein a transversal extension of a head of the resilient beam is wider than a gap between the carrier
and the chassis causing the head of the resilient beam to abut a distal face on the recess in the chassis while being prevented
from deflecting in an inward direction by the carrier or to abut a distal face on the recess in the carrier while being prevented
from deflecting in an outward direction by the chassis thereby forwarding load from the control spring to the carrier for
needle insertion, wherein the resilient beam is arranged to be switched between the chassis and the carrier by ramped engagement
of the head to the distal faces under load of the control spring depending on the relative longitudinal position between the
chassis and the carrier.

US Pat. No. 9,345,840

DRUG DELIVERY DOSE SETTING MECHANISM WITH VARIABLE MAXIMUM DOSE

Sanofi-Aventis Deutschlan...

1. A drug delivery device having a variable maximum dose, said device comprising:
a housing, said housing comprising
a helical groove, and
a plurality of ratchet teeth;
a dial sleeve rotatably coupled to said helical groove of said housing, and
a first stop component engaging a first set of said plurality of ratchet teeth of said housing, said first stop component
located at a first stop location along an outer surface of said housing defining a first maximum dose of said drug delivery
device;

wherein said dial sleeve moves said first stop component to a second set of said plurality of said ratchet teeth so that said
first stop component moves along said outer surface of said housing to a second stop location, said second stop location defining
a second maximum dose of said drug delivery device, and

wherein said first stop component is user-adjustable (i) from said first stop location to said second stop location and (ii)
from said second stop location to said first stop location, such that the variable maximum dose for the drug delivery device
can be increased and decreased.

US Pat. No. 9,192,726

DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A drug delivery device comprising;
a housing;
a plurality of contacts; and
a cylindrical member configured to be rotatably supported inside the housing, wherein the outer surface of the cylindrical
member is provided with a plurality of tracks together forming an encoder, each track comprising conductive segments and non-conductive
segments, and wherein the cylindrical member is supported in the housing such that each track is engaged by a respective one
of the plurality of contacts,

wherein the plurality of tracks are arranged into first and second banks of tracks; and a switch configured:
in a first position, to electrically connect the first and second banks of tracks; and
in a second position, to electrically isolate the first and second banks of tracks.

US Pat. No. 9,649,576

GAS-LIQUID SEPARATOR

SANOFI-AVENTIS DEUTSCHLAN...

1. A gas-liquid separator, comprising:
a chamber extending in an axial direction (z) and having at least a flow chamber portion extending into a collection chamber
portion,

a deflector arranged in the flow chamber portion, the deflector having a deflector panel extending radially outwardly (r)
and in axial direction (z) to form a narrowing flow channel between the deflector and a side wall of the chamber, wherein
the deflector panel has a free edge,

at least one gas outlet shielded by the deflector panel and being arranged axially offset from the free edge, and
an inlet duct extending into the chamber in axial direction (z), wherein the inlet duct branches off into a plurality of radially
extending inlets at a proximal end of the chamber.

US Pat. No. 9,408,970

SYRINGE CARRIER

Sanofi-Aventis Deutschlan...

1. An injection device comprising:
a syringe comprising a barrel and a needle mounted to the barrel;
a needle shield covering the needle of the syringe; and
a syringe carrier comprising a body within which the barrel of the syringe is received, the body having a cylindrical shape
with a first diameter and including a distal portion having one or more barbs, and the one or more barbs being resilient and
engaging a circumferential gap between the barrel of the syringe and the needle shield,

wherein the distal portion of the body is enlarged and has a second diameter greater than the first diameter of the body to
allow insertion of a cylindrical tool having an open end adapted to receive the needle shield, the tool having a third diameter
substantially equal to the second diameter, and

wherein the one or more barbs are adapted to deflect when engaged by the tool to allow the needle shield to pass the one or
more barbs in a distal direction.

US Pat. No. 9,108,001

DRUG DELIVERY DEVICE WITH PISTON ROD CARRYING DOSE MARKINGS

Sanofi-Aventis Deutschlan...

1. A drug delivery device comprising:
a housing with a proximal end and a distal end,
a cartridge holder adapted to retain a cartridge, the cartridge holder comprising an at least partially transparent side wall,
a piston rod, the piston rod being adapted to drive a piston so as to engage the piston into the cartridge, and
a plurality of symbols on the piston rod, the symbols representing dosage information during operation of the drug delivery
device and being visible through a window aperture in the housing or in the cartridge holder

wherein a filling status of the drug delivery device is recognizable by viewing at least one of the symbols on the piston
rod through the window aperture

wherein only one symbol is viewed through the window aperture at a time on the piston rod and this particular viewed symbol
represents an amount of medicinal product delivered

wherein the at least partially transparent side wall of the cartridge holder comprises a plurality of structural elements
located on an inner surface of the side wall, the structural elements being transparent and being capable of unevenly reflecting
light so as to at least partially render the symbols of the piston rod unreadable, wherein the structural elements comprise
facets, undulating elements, or grooves.

US Pat. No. 9,084,853

DRIVE MECHANISM FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A drive mechanism for a drug delivery device, comprising:
a lead screw comprising a first screw thread,
a lead screw nut and
a drive member, aligned with an axis defining an axial direction and an opposite axial direction,
a coupling between the lead screw and the lead screw nut allowing a helical movement of the lead screw with respect to the
lead screw nut at least in the axial direction,

the drive member being rotationally locked with the lead screw nut,
the lead screw being coupled with the drive member, the coupling generating a helical movement of the lead screw with respect
to the drive member when the drive member is moved in the axial direction with respect to the lead screw, and

the coupling being overridden to prevent a helical movement of the lead screw with respect to the drive member when the drive
member is moved in the opposite axial direction with respect to the lead screw,

spline features of the lead screw, the spline features being arranged in at least one row parallel to the axis with alternatingly
small and large gaps between succeeding spline features, and

a stop feature of the drive member, the stop feature facing the lead screw, a dimension of the stop feature in the direction
of the axis being larger than the small gaps and at most as large as the large gaps.

US Pat. No. 9,586,722

WORKPIECE CARRIER FOR TRANSPORTING AND/OR STORING COMPONENTS OF DRUG DELIVERY DEVICES

SANOFI-AVENTIS DEUTSCHLAN...

1. A workpiece carrier for transporting or storing components of a drug delivery device, comprising:
an array of accommodating recesses extending in a first lateral plane (x, y) and being adapted to receive at least one component
of the drug delivery device,

at least one stack forming structure formed to mate with a corresponding stack forming structure of another workpiece carrier
for mutually aligning workpiece carriers when stacked on one another,

wherein the center of the at least one stack forming structure is arranged laterally offset with respect to the center of
the array of accommodating recesses in at least one lateral direction (x, y) lying in the first lateral plane, and

wherein the at least one stacking forming structure comprises a surrounding edge comprising at least in sections a corrugated
or undulated structure; and

wherein the at least one stacking forming structure comprises at least one outwardly extending projection having an inward
directed ledge at a lower end formed to abut against a flange portion of another workpiece carrier stacked beneath in a first
orientation.

US Pat. No. 9,533,105

DRIVE MECHANISMS SUITABLE FOR USE IN DRUG DELIVERY DEVICES

Sanofi-Aventis Deutschlan...

1. A drive mechanism for use in a drug delivery device
comprising:
a housing comprising a window at a distal end of the housing, where the window has a maximum dose stop;
a dose dial sleeve being rotatable with respect to the housing and having a radial stop extending radially outward from an
outer surface of the dose dial sleeve, the radial stop configured to engage the maximum dose stop;

a drive sleeve;
and a piston rod engaged with the drive sleeve.

US Pat. No. 9,488,288

ACTIVE VALVE FOR DRUG DELIVERY

SANOFI-AVENTIS DEUTSCHLAN...

1. A valve arrangement, comprising:
a valve body comprising a fluidic channel having an outlet port; and
a valve piston, the valve piston comprising a through opening connecting an end with a piercing end that provides fluid communication
between the piercing end and the outlet port to allow fluid to pass through the valve piston, and the valve piston comprising
an outer lateral surface having a circular recess formed therein,

wherein the valve piston is moveable within the valve body between a first longitudinal position and a second longitudinal
position,

wherein the circular recess of the valve piston is not in fluid communication with the outlet port, to disable a fluid flow
between the outlet port and the end via the circular recess, when the valve piston is in the first longitudinal position within
the valve body, and

wherein the circular recess of the valve piston is in fluid communication with the outlet port, to enable the fluid flow between
the outlet port and the end, when the valve piston is in the second longitudinal position within the valve body.

US Pat. No. 9,366,673

PORPHYROMONAS GINGIVALIS POLYPEPTIDES

Sanofi Pasteur Limited, ...

1. An immunogenic composition comprising at least one isolated polypeptide, an adjuvant that induces a Th2-biased immune response,
and a pharmaceutically acceptable carrier, wherein the at least one polypeptide is selected from the group consisting of Porphyromonas gingivalis protein PG2172 (SEQ ID NO. 3), a polypeptide having at least 80% identity to SEQ ID NO. 3, an immunogenic fragment of 8, 9,
10, 12, 13, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or more consecutive amino acids of SEQ ID NO. 3,
and a variant comprising a conservative substitution of at least one amino acid of SEQ ID NO. 3.

US Pat. No. 9,345,838

DRUG DELIVERY DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A disposable drug delivery device for selecting and dispensing a number of user variable doses of a medicament, comprising
a housing, a cartridge holder for retaining a cartridge containing the medicament, a piston rod displaceable relative to the
cartridge holder, a driver coupled to the piston rod, a display member for indicating a set dose and being coupled to the
housing and to the driver, and a button coupled to the display member and to the driver, wherein the drug delivery device
comprises at least one of the following features:
the housing comprises an outer body and an inner body, wherein the outer body and the cartridge holder comprise a single,
one-piece component,

the driver is in threaded engagement with the piston rod, permanently rotationally locked to the button and axially displaceable
relative to the button in a proximal direction against the force of a resilient member which is a one piece component with
either the driver or the button,

the housing comprises an inner surface with splines and the driver comprises at least one protrusion which in a first axial
position of the button relative to the driver is allowed to elastically move in a radial direction and which in a second axial
position of the button relative to the driver is forced by the button in a radially outer position thus rotationally locking
the driver to the housing,

a first rotationally acting clutch is formed by the button and the display member which is in its coupled state during dose
setting and in its decoupled state during dose dispensing, and a second rotationally acting clutch formed by the driver and
the housing which is in its decoupled state during dose setting and in its coupled state during dose dispensing,

a first clicker is formed by the driver and the housing which is active during dose setting and a second clicker formed by
the button and the display member which is active during dose dispensing,

the number of components of the drug delivery device including the cartridge and a cap for shielding the cartridge holder
is ten or less.

US Pat. No. 9,295,789

RING CENTER NEEDLE

Sanofi-Aventis Detuschlan...

1. An apparatus comprising:
a needle guide configured to at last partially receive a needle of a needle assembly in a longitudinal opening and to center
said needle of said needle assembly in said longitudinal opening, wherein said needle guide is longitudinally compressible,
wherein the longitudinal opening is defined by a longitudinally compressible lateral surface, and wherein the lateral surface
has at least one longitudinal slit.

US Pat. No. 9,072,841

MEDICATED MODULE WITH AUTOMATIC RESERVOIR ENGAGEMENT

Sanofi-Aventis Deutschlan...

1. A medicated module attachable to a drug delivery device, comprising,
an outer housing having an inner surface, a proximal end and a distal end, where the proximal end comprises an upper hub holding
a first double-ended needle cannula and a connector configured for attachment to a drug delivery device;

a locking disc comprising a radial protrusion;
a lower hub comprising a radial protrusion;
a bypass housing comprising non-linear slots that rotatably and slidably engage radial protrusion on the locking disc and
the radial protrusion on the lower hub;

a reservoir within the bypass housing comprising a single dose of a medicament;
a rotating cylinder comprising an outer surface that comprises a non-linear track;
a guard having inner and outer walls, where the inner wall comprises a drive tooth that engages the non-linear track on the
outside surface of the rotating cylinder,

where an inside surface of the cylinder comprises radial protrusions that engage the radial protrusions on the locking disc
and the radial protrusion on the lower hub, and

a biasing member engaged between the guard and the lower hub.

US Pat. No. 9,072,842

METHOD AND APPARATUS FOR PENETRATING TISSUE

SANOFI-AVENTIS DEUTSCHLAN...

1. A medicament delivery system, comprising:
a housing member;
one or more penetrating members positioned in a cartridge;
a controllable driver configured to be coupled to the one or more penetrating members;
a processor configured to be coupled to each penetrating member and the controllable driver, the processor customizing a user's
profile in response to user input information, the processor providing for localization of an injection of a medicament, the
processor allowing the user to rank the results of penetrating event configured to customize a user profile;

a database that stores information relative to penetrating events, with the processor calculating profile traits, in response
to circumstances or parameters for a lancing input by a user.

US Pat. No. 9,061,106

SAFETY DEVICE FOR A PRE-FILLED SYRINGE AND AN INJECTION DEVICE

SANOFI-AVENTIS DEUTSCHLAN...

1. A safety device for a pre-filled syringe comprising
a support body adapted to mount the pre-filled syringe,
a first needle shield slidably arranged with respect to the support body and
a second needle shield slidably arranged with respect to the support body and releasably retained in a retracted position
(PR), wherein a proximal movement of the first needle shield with respect to the support body releases the retention of the
second needle shield in the retracted position (PR), characterized in that the second needle shield comprises a helical recess
accommodating a projection of the support body so that the second needle shield is allowed to slide parallel to a central
axis (A) of the safety device in the distal direction towards an advanced position (PA) wherein the helical recess is configured
to force the second needle shield to rotate with respect to the support body when the second needle shield is allowed to slide
parallel to a central axis (A).

US Pat. No. 9,561,330

PEN-TYPE DRUG INJECTION DEVICE WITH OPTICAL DOSE ENCODING AND DECODING SYSTEM

SANOFI-AVENTIS DEUTSCHLAN...

1. A method of decoding encoded information comprising optically encoded images, the method comprising:
controlling one or more sensors to periodically check for motion of a movable component of a drug delivery device having encoded
information thereon;

if motion of the movable component is detected, preventing a first encoded information reading and decoding process from being
performed;

when motion of the movable component is not detected, performing the first encoded information reading and decoding process;
the method further comprising controlling one or more light sources to illuminate the movable component of the drug delivery
device during the periodic check for motion of the movable component.

US Pat. No. 9,248,245

AUTO-INJECTOR

Sanofi-Aventis Deutschlan...

1. An auto-injector for administering a dose of a liquid medicament (M), comprising:
an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing
the medicament (M), the housing having a distal end (D) and a proximal end (P) with an orifice intended to be applied against
an injection site, wherein the syringe is slidably arranged with respect to the housing,

spring capable of, upon activation:
pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal
end (P),

operating the syringe to supply the dose of medicament (M), and
retracting the syringe with the needle into the covered position after delivering the medicament (M),
activator arranged to lock the spring in a pressurized state prior to manual operation and capable of, upon manual operation,
releasing the spring for injection,

wherein the spring is a single compression spring arranged to be grounded at a distal end in the housing for advancing the
needle and for injecting the dose of medicament (M) via a plunger and wherein the compression spring is arranged to have its
ground in the housing switched to its proximal end while the distal end of the compression spring is released from its ground
in the housing for retracting the syringe, and

wherein a retraction sleeve is axially movable arranged in the housing, wherein at least one latch is provided for axially
fixing the refraction sleeve in a maximum proximal position, wherein the compression spring is arranged inside the retraction
sleeve with its distal end bearing against a distal end face and with its proximal end bearing against a thrust face of a
decoupling member, wherein the decoupling member is arranged to decouple the latch when being moved in a proximal direction
(P) nearly into a maximum proximal position, thus allowing the retraction sleeve to move in distal direction (D) and retract
the needle.